Pre 2000

Publications Grants Research Degrees

Publications

Dixon G, Dissanaike S, Harper CG. Parvalbumin-immunoreactive neurons in the human anteroventral thalamic nucleus. Neuroreport 2000; 11: 96-100.

Catts S, Fox A, Ward P, McConaghy N. Schizotypy: phenotypic marker as risk factor. Australian & New Zealand Journal of Psychiatry 2000; 34: S101-107.

Catts SV, O’Toole BI, Draganic DM. Editorial – Proceedings of the First Australian Schizophrenia Prevention Conference. Australian and New Zealand Journal of Psychiatry 2000; 34 (Supplement): S1-S5.

Catts SV, O’Toole BI, Draganic DM. Proceedings of the First Australian Schizophrenia Prevention Conference. Australian and New Zealand Journal of Psychiatry 2000; 34 (Supplement): S1-S212.

Le Corre S, Lopez P, Catts S, Ward P, Harper C. Increased levels of expression of an NMDA-R1 splice variant in the superior temporal gyrus in schizophrenia. Neuroreport 2000; 11: 983-986.

Mitchell M. What genetic advances might mean for the consumer in mental illness. Australian & New Zealand Journal of Psychiatry 2000; 34: S198-S200.

Peterson D. The ethics of research into schizophrenia prevention: a carer’s perspective. Australian & New Zealand Journal of Psychiatry2000; 34: S201-S203.

Tooney PA, Au GG, Chahl L. Localisation of tachykinin NK1 and NK3 receptors in the human prefrontal and visual cortex. Neuroscience Letters2000; 283: 185-188.

Tooney PA, Au GG, Chahl LA. NK1 and NK3 receptors in the prefrontal cortex of the human brain. Clinical and Experimental Physiology and Pharmacology 2000; 27: 947-949.

Ward P. Structural brain imaging and the prevention of schizophrenia: can we identify neuroanatomical markers for young people at risk for the development of schizophrenia? Australian & New Zealand Journal of Psychiatry 2000; 34: S127-S130.

Williams L, Brammer M, Skerrett D, Lagopoulos J, Rennie C, Kozek K, Olivieri G, Peduto A, Gordon E. The neural correlates of orienting: an integration of fMRI and skin conductance orienting. Neuroreport 2000: 11; 3011-3015.

Grants

Schizophrenia Research Institute Administered

Tooney P. Tachykinin NK1 receptor immunoreactivity is increased in the prefrontal cortex in schizophrenia (International Congress on Schizophrenia Research). Ian Potter Foundation Travel Grant, 2001 ($1,500).

Ward P, Catts S, Draganic D. The Rebecca Cooper Foundation Postgraduate Scholarship for Schizophrenia Research. The Rebecca Cooper Medical Research Foundation, 1999-2001 ($75,000).

Catts S, Ward P. Health/Science Project – Neuroscience Institute of Schizophrenia and Allied Disorders (NISAD). The Sylvia and Charles Viertel Charitable Foundation, 1997-2000 ($240,000).

Catts S. Establishment of the NISAD Tissue Donor Program. The Sidney Myer Fund, 1997 ($21,500).

Catts S. NISAD. The Andrew Thyne Reid Trust, 1996($100,000).

Host Institution Administered

Chahl L, Tooney P, Dunkley P, Rostas J, Van Helden D, Sim A, Callister RJ, Dickson P, Brichta A. Neurolucida imaging system. NHMRC Equipment Grant / University of Newcastle RMC, 2000 ($48,000).

Harper C. Brain tissue resource centre for alcohol research. National Institute of Alcoholism and Alcohol Abuse (NIAAA), 2000-2003 ($1,083,702).

Huang XF. Acquisition system for physiological and behavioural data. University of Wollongong MRC RIBG Grant, 2000 ($37,650).

Huang XF, Zavitsanou K. Neural membrane phospholipid composition and antipsychotic drug binding efficiency in schizophrenia. University of Wollongong Metabolic Research Centre, 2000 ($6,500).

Karayanidis F, Carr V, Johnston P, Schall U. Computer software for the analysis of event-related brain wave recordings in conjunction with functional brain imaging in young patients with schizophrenia. RMC Project Grant, University of Newcastle, 2000 ($8,000).

Schall U, Ward P, Bender S, Lagopoulos J, Little C. A functional magnetic resonance imaging investigation of brain activation during performance of the ‘Tower of London’. University of Newcastle New Staff Grant, 2000 ($9,000).

Schall U, Ward P, Johnston P, Carr V. Combined ERP/fMRI in young patients with schizophrenia. RMC Project Grant, University of Newcastle, 2000 ($12,000).

Tooney P. The effect of antipsychotic medication on the expression of tachykinin receptors in the guinea pig brain. University of Newcastle Early Career Researcher Grant, 2000 ($4,500).

Bell W, Huang XF. The role of neural membrane phospholipid composition in schizophrenia. University of Wollongong MRC Honours Scholarship, 2000 ($2,250).

Chahl L, Tooney P, Yip J. Distribution of tachykinin receptors in the limbic regions of the human brain. Hunter Medical Research Institute, 1999-2000 ($25,000).

Harper C, Dixon G. Tissue processor: an infrastructural facility for research groups interested in the study of human brain disease. The Clive and Vera Ramaciotti Foundation, 1999 ($15,000).

Harper C, Dixon G. Research cryostat: an infrastructural facility for research groups interested in the study of alcoholic related brain damage. The Australian Brewer’s Foundation, 1999 ($13,500).

Hickie I, Ward P, Turner K, Naismith S, Scott E, Shnier R. Delineating the anatomical correlates of neurocognitive and psychomotor dysfunction in depression by functional magnetic resonance imaging. NHMRC Project Grant, 2000-2002 ($395,000).

Williams L, Harris A, Gordon E. The effects of risperdal on emotional wellbeing and clinical outcome in schizophrenia. Australasian Janssen-Cilag Clinical Research Grant, 2000 ($62,000).

Chahl L, Tooney P. C Mount Colour Video Camera. University of Newcastle Faculty of Medicine and Health Sciences Equipment Grant, 1999 ($5,700).

Research Degrees

Honours

Warren Bell, University of Wollongong

Hazel Hill, University of Sydney

Yasmin Ferguson, University of Newcastle

Summer Student Scholarships

Warren Bell, University of Wollongong

Zana Gluseska, University of Wollongong

Jane Carland, University of Sydney

Joseph Rizk, University of Sydney

Virginia Crawter, University of Newcastle

Julie Preston, University of Newcastle

Gough Au, University of Newcastle

Sharmila Dissanaike, University of Sydney

2001

Publications Grants Research Degrees

Publications

Boyes M, Mitchell M. Volunteer brain donation after death for schizophrenia research: consumer and researcher viewpoints.Proceedings of the Australian Institute of Health, Law and Ethics 6th Annual Conference, Melbourne, Australia, July 2001. (http://www.law.unimelb.edu.au/aihle/proceedings.html#sixth)

Dixon G, Harper C. An analysis of GAD immunoreactivity elements in the anterior thalamus of the human brain. Brain Research 2001; 923: 39-44.

Johnston P, Katsikitis M, Carr V. A generalised deficit can account for problems in facial emotion recognition in schizophrenia. Biological Psychology 2001; 58: 203-227.

Loughland C, Carr V, Lewin T. The NISAD Schizophrenia Research Register: Why do we need a database of schizophrenia volunteers?Australian and New Zealand Journal of Psychiatry 2001; 35: 660-667.

Tooney PA, Crawter VC, Chahl LA. Increased expression of tachykinin NK1 receptors in the prefrontal cortex in schizophrenia. Biological Psychiatry 2001; 49: 523-527.

Williams LM, Phillips ML, Brammer MJ, Skerrett D, Lagopoulos J, Rennie C, Bahramali H, Olivieri G, David AS, Peduto A, Gordon E. Arousal dissociates amygdala and hippocampal fear responses: Evidence from simultaneous fMRI and skin conductance recording. NeuroImage 2001; 14: 1070-1079.

Grants

Schizophrenia Research Institute Administered

Draganic D, Ward P. The St George Bank Foundation Scholarship for Schizophrenia Research. The St George Foundation, 2002-2004 ($75,000).

Host Institution Administered

Baker A, Schall U. Software tool integrating EEG and event-related potential measurement with structural and functional magnetic resonance imaging. NHMRC Equipment Grant and University of Newcastle Infrastructure Block Grant, 2001 ($24,000).

Harper C, Dixon G, Chu Y, Johnston G. Phosphorimager screens and cassettes for ligand autoradiography. University of Sydney Blackburn Research Precinct Grant, 2001 ($6,650).

Huang XF, Zavitsanou K. Can dietary intervention enhance drug efficiency in treating schizophrenia? University of Wollongong URC New Partnership Grant, 2001-2002 ($10,000).

Huang XF, Zavitsanou K. Correlation between neural membrane phospholipid composition and atypical antipsychotic drug binding in schizophrenia. University of Wollongong Metabolic Research Centre Grant, 2001 ($2,270).

Johnston P. The Hunter Medical Research Institute Young Investigator of the Year. Hunter Medical Research Institute, 2001 ($5,000).

Karayanidis F, Schall U. Task switching in schizophrenia: use of internally-generated and externally-triggered cues. RMC Project Grant, University of Newcastle, 2001 ($11,000).

Kent A, Fox A, Jablensky A. Functional neuroanatomy of sustained attention, working memory and inhibition deficits in schizophrenia. NHMRC Network Neuroimaging Consortium Grant, 2001 ($2,000).

Schall U, Michie P, Ward P, Todd J, Johnston P. Event-related fMRI pilot study on auditory sensory memory. NHMRC Neuroimaging Consortium, 2001 ($5,000).

Schall U, Tooney P et al. Clinical Neuroscience Program -80�C freezer. Faculty of Medicine and Health Sciences Equipment Grant, 2001 ($20,895).

Tooney P, Chahl L. The effects of tachykinin NK1 receptor antagonists on stress responses associated with opioid withdrawal. University of Newcastle RMC Grant, 2001 ($9,000).

Tooney P, Scott R, Chahl L, Carr V. Investigating changes in gene expression in psychosis using microarray technology. Hunter Medical Research Institute Clinical Neuroscience Program, 2001-2002 ($76,500).

Tooney P. Development of microarray technology for biomedical research in Newcastle. Hunter Medical Research Institute Young Investigator Award, 2001-2003 ($21,000).

Tooney P. Tachykinin NK1 receptor immunoreactivity is increased in the prefrontal cortex in schizophrenia (International Congress on Schizophrenia Research). University of Newcastle, School of Biomedical Sciences, 2001 ($1,000).

Zavitsanou K, Huang XF, Mattner F, Katsifis A. Detection of structural changes in post mortem brain of schizophrenia patients and in rat brain after phencyclidine administration. Australian Institute of Nuclear Science and Engineering Grant, 2001-2002 ($16,645).

Research Degrees

Honours

Kelly Newell, University of Wollongong

Summer Student Scholarships

Warren Bell, University of Wollongong

David Burns, University of Wollongong

Kelly Newell, University of Wollongong

Virginia Crawter, University of Newcastle

Sonja Schleimer, University of Sydney

2002

Publications Grants Research Degrees

Publications

Carr V, Lewin T, Barnard R, Walton J, Allen J, Constable P, Chapman J. Comparisons between schizophrenia patients recruited from Australian general practices and public mental health services. Acta Psychiatrica Scandinavica 2002; 105: 346-355.

Laws S, Hone E, Taddei K, Harper C, Dean B, McClean C, Masters C, Lautenschlager N, Gandy S, Martins RVariation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E.Molecular Psychiatry 2002; 7: 886-890.

Loughland C, Williams L, Gordon E. Visual scanpaths to positive and negative facial emotions in an outpatient schizophrenia sample.Schizophrenia Research 2002; 55: 159-170.

Loughland C, Williams L, Gordon E. Schizophrenia and affective psychosis show different visual scanning behaviour for faces: A trait verses state-based distinction. Biological Psychiatry 2002; 52: 338-348.

Sarris M, Garrick T, Sheedy D, Harper C. An Australian Experience in Brain Banking: the New South Wales Tissue Resource Centre. Pathology2002; 34: 225-229.

Zavitsanou K, Huang XF. Decreased [3H] spiperone binding in the anterior cingulate cortex in schizophrenia: an autoradiographic study.Neuroscience 2002; 109: 709-716.

Zavitsanou K, Ward P, Huang XF. Selective alterations of iontropic glutamate receptors in anterior cingulate cortex in schizophrenia.Neuropsychopharmacology 2002; 27: 826-833.

Grants

Schizophrenia Research Institute Administered

Draganic D, Tooney P, Ward P. Analysis of gene expression in schizophrenia using genetic technology: NISAD PhD scholarship for schizophrenia research. The Ronald Geoffrey Arnott Foundation, 2002-2003 ($10,000).

Draganic D, Tooney P, Ward P. Analysis of gene expression in schizophrenia using genetic technology: NISAD PhD scholarship for schizophrenia research. The Perpetual Foundation, 2002-2003 ($10,000).

Draganic D, Ward P. Project Teen Rescue: Fighting Youth Suicide. The Telstra Foundation, 2002-2003. ($40,000)

Host Institution Administered

Clunas N. Brain mechanisms of attention problems in people with schizophrenia and bipolar disorder. Australian Rotary Health Research Fund Ian Scott Fellowship, 2002-2005 ($91,000).

Cohen M, Carr V, Johnston P, Schall U. Functional and structural brain imaging of executive function in chronic cannabis users and cannabis using first episode schizophrenia patients. Hunter Medical Research Institute Grant, 2002 ($15,000).

Huang XF, Ward P, Zavitsanou K. New animal model to investigate anti-psychotic drug-induced obesity and related metabolic disorders. University of Wollongong MRC Grant, 2002 ($8,000).

Huang XF, Zavitsanou K, Newell K. Neural pathophysiology of posterior cingulate cortex in schizophrenia. University of Wollongong URC / MRC Grant, 2002-2004 ($30,000).

Loughland C, Johnston P. Visual scanpaths to dynamic facial expression stimuli in schizophrenia (Viewpoint eye tracker). Hunter Medical Research Institute Clinical Neuroscience Program Grant, 2002 ($9,000).

Loughland C, Johnston P. Visual scanpaths to dynamic facial expression stimuli in schizophrenia (Viewpoint eye tracker). University of Newcastle Faculty of Health Equipment Grant, 2002 ($10,220).

Schall U, Ward P, Michie P, Thompson P. Brain imaging studies of auditory processing dysfunctions in schizophrenia. NHMRC Project Grant, 2003-2005 ($357,500).

Schall U. Computer server system for brain imaging laboratory at the Centre for Mental Health Studies. University of Newcastle Infrastructure Block Grant, 2002 ($14,000).

Scott R, Tooney P, Rostas J, Dickson P, Calford M. Computer software and hardware package for the analysis of gene expression profiles. University of Newcastle, School of Biomedical Sciences Research Infrastructure Block Grants, 2002 ($35,865).

Tooney P, Loughland C, Scott R, Carr V. Establishment of a DNA Bank to facilitate the investigation of the genetics of schizophrenia and other brain disorders. Hunter Medical Research Institute Clinical Neuroscience Program, 2002 (33,500).

Ward P, Coltheart M, Langdon R, Rossell S. A neuropsychological investigation of primary and secondary delusions. Health Research Foundation Sydney South West Research Grant, 2002-2003 ($20,300).

Zavitsanou K. Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia (Third Forum of European Neuroscience). University of Wollongong, Metabolic Research Centre, 2002 ($1,000).

Research Degrees

Doctor of Philosophy

Dr Melissa Green, University of Sydney

Dr Carmel Loughland, University of Sydney

Honours

Rebecca Hannan, University of Newcastle

Matthew Hughes, University of Newcastle

Andrea Kerr, University of Newcastle

Sonja Schleimer, University of Sydney

Summer Student Scholarships

Wayne Anderson, University of Newcastle

Sinthu Sithamparanathan, University of Sydney

Tu Hao Tran, University of Sydney

2003

Publications Grants Research Degrees

Publications

Andresen R, Oades L, Caputu P. The experience of recovery from schizophrenia: towards an empirically-validated stage model. Australian and New Zealand Journal of Psychiatry 2003; 37: 586-594.

Boyes M, Ward P. Brain donation for schizophrenia research: gift, consent and meaning. Journal of Medical Ethics 2003; 29: 165-168.

Dean B, Laws S, Hone E, Taddei K, Scarr E, Harper C, McCLean C, Masters C, Lautenschlager N, Gandy S, Martins R. Increased levels of apolipoprotein E in the frontal cortex from subjects with schizophrenia.Biological Psychiatry 2003; 54: 616-622.

Garrick T, Azizi L, Merrick J, Harper C. Brain donation for research: what do the next of kin say (letter)? Internal Medicine Journal 2003; 33: 475.

Green M, Williams L, Davidson D. Visual scanpaths to threat-related faces in deluded schizophrenia. Psychiatry Research 2003; 119: 271-285.

Harper C, Dixon G, Sheedy D, Garrick T. Neuropathalogical alterations in alcoholic brains: studies arising from the NSW Tissue Resource Centre.Progress of Neuropsychopharmacology and Biological Psychiatry 2003; 27: 951-961.

Harper C, Garrick T, Matsumoto I, Pfefferbaum A, Adalsteinsson E, Sullivan E, Dodd P, Lewohl J, Butterworth R. How important are brain banks for alcohol research? Alcoholism: Clinical and Experimental Research 2003; 27: 310-323.

Johnston P, McCabe K, Schall U. Differential susceptibility to performance degredation across categories of facial emotion – a model confirmation. Biological Psychology 2003; 63: 45-58.

Schall U, Johnston P, Lagopoulos J, J�ptner M, Jentzen W, Thienel R, Dittman-Balcar A, Bender S, Ward P. Functional brain maps of Tower of London performance: a PET and fMRI study. Neuroimage 2003; 20: 1154-1161.

Schall U, Johnston P, Todd J, Ward P, Michie P. Functional neuroanatomy of auditory sensory memory: an event-related fMRI study.Neuroimage 2003; 20: 729-736.

Thomas E, Laws S, Sutcliffe G, Harper C, Dean B, McCLean C, Masters C, Lautenschlager N, Gandy S, Martins R. Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer’s disease: no relation to apolipoprotein E expression or genotype. Biological Psychiatry2003; 54: 136-141.

Williams L, Loughland C, Green M, Harris A, Gordon E. Improved emotion perception in schizophrenia: An eye movement study comparing treatment with risperidone versus haloperidol. Psychiatry Research 2003; 120: 13-27.

Grants

Schizophrenia Research Institute Administered

Draganic D, Tooney P, Ward P. A DNA Bank for schizophrenia research. The Baxter Charitable Foundation, 2003 ($15,000).

Draganic D, Tooney P, Ward P. Analysis of gene expression in schizophrenia using genetic technology: NISAD PhD Scholarship for Schizophrenia Research. JS Love Trust, 2003-2004 ($20,000).

Draganic D, Ward P. Polhemus digitiser for schizophrenia research. The Cecilia Kilkeary Foundation, 2003 ($8,920).

Draganic D, Ward P. Viewpoint eye tracking system. The Macquarie Bank Foundation, 2003 ($13,000).

Loughland C. Schizophrenia and affective disorder show different visual scanpath patterns to faces and facial expressions: Is this a trait versus state-based distinction? Ian Potter Foundation Travel Grant, 2003 ($2,000).

Ward P, McGrath J. Linking clinical and basic research in order to understand the causes of schizophrenia: A collaborative network to study animal models of schizophrenia. The Sylvia and Charles Viertel Charitable Foundation, 2003-2004 ($120,000).

Host Institution Administered

Budd B, Michie P, Todd J, Schall U. Integrity of auditory temporal processing in the ascending auditory system in schizophrenia. Hunter Medical Research Institute Young Investigator Award, 2003 ($10,000).
Chahl L, Carr V, Tooney P, Loughland C, Calford M, Michie P. Assessment of somatosensory function in subjects with schizophrenia: touch, pain and axon reflex flare. University of Newcastle RGC Grant, 2003 ($11,000).

Chetcuti A. Identification of potential drug targets for bipolar disorder by microarray profiling gene expression in an animal model of anti-manic drug action. World Congress on Psychiatric Genetics Travel Scholarship, 2003 ($2,280).

Cohen M, Johnston P, Schall U. Functional and structural brain imaging of executive function in chronic cannabis users using first episode of schizophrenia patients. Neuroscience Research Grants – Pfizer, 2003 ($55,000).

Coltheart M et al. The Centre for Cognitive Science and Cognitive Neuropsychology. ARC Centre for Excellence Grant, 2003-2005 ($2.2M).

Harper C. Brain tissue resource center for alcohol research. National Institute of Alcoholism and Alcohol Abuse (NIH), 2003-2008 ($2,268,258).

Harper C. ‘Using our Brains': a brain donor program to promote research into the efects of alcohol on the human brain. The Australian Brewer’s Foundation Medical Research Grant, 2003-2004 ($32,560).

Huang X, Zavitsanou K. Unravelling the neuropathology of atypical anti-psychotic drug-induced metabolic disorders in schizophrenia. University of Wollongong URC Grant, 2003-2006 ($35,000).

Hughes M. Stop signal inhibition: an fMRI investigation. Australasian Society for Psychiatric Research Travel Grant-in-Aid, 2003 ($1,000).

Langdon R, Ward P. Cognitive neuropsychiatry: understanding delusional belief and delusional hallucination from a cognitive neuropsychological perspective. ARC Discovery Grant, 2004-2008 ($410,825).

Matsumoto I. Brain bank and donor program for biomedical research into schizophrenia and alcohol-related brain damage. New South Wales BioFirst Award, 2003-2005 ($330,000).

Michie P, Schall U, Ward P, Thompson P, Todd J, Spencer E, Johnston P. Polhemus fastrack digitiser with accessories. NHMRC Equipment Grant, 2003 ($20,000).

Ross F, Tooney P. Investigation of the contribution of the use of cannabis in the development of schizophrenia in genetically predisposed individuals. Hunter Medical Research Institute Grant, 2003-2004 ($16,000).

Solowij N, Grenyer B. Neurocognitive and biochemical correlates of memory impairment associated with long term heavy cannabis use. University of Wollongong, 2003 ($6,000).

Solowij N, Ward P, Shnier R, Grenyer B. Neurocognitive and biochemical correlates of memory impairment associated with long term heavy cannabis use. The Clive and Vera Ramaciotti Foundation, 2003 ($30,000).

Zavitsanou K, Mattner F, Huang X, Newell K, Katsifis A. Investigation of muscarinic receptors in the anterior cingulate cortex in schizophrenia. Australian Institute of Nuclear Science and Engineering Grant, 2003 ($18,225).

Research Degrees

Doctor of Philosophy

Dr Tina Hinton, University of Sydney

Dr Ryan McKay, Macquarie University

Masters / Clinical Doctorate

Therese Garrick, University of Sydney

Lydia Meem, University of Newcastle

Honours

Kimberley Alexander, University of Sydney

Mathana Packianathan, University of Sydney

Tu Hao Tran, University of Sydney

Sharon Monterrubio, University of Wollongong

David, University of Wollongong

Summer Student Scholarships

Wayne Anderson, University of Newcastle

Mary-Claire Hanlon, University of Newcastle

Jessica Hansen, University of Newcastle

Renee Granger, University of Sydney

Simon Howell, University of Sydney

Wan Yi Ng, University of Sydney

Nicholas Kerr, Garvan Institute of Medical Research

Sharon Monterrubio, University of Wollongong

2004

Publications Grants Research Degrees

Publications

Breakspear M, Brammer M, Das P, Bullmore E, Williams L. Spatio-temporal wavelet resampling for functional neuroimaging data. Human Brain Mapping 2004: 23: 1-25.

Carr V, Lewin T, Barnard R, Walton J, Allen J, Constable P, Chapman J. Attitudes and roles of general practitioners in the treatment of schizophrenia compared with community mental health staff and patients.Social Psychiatry and Psychiatric Epidemiology 2004; 39:78-84.

Dixon G, Garrick T, Whiteman I, Sarris M, Sithamparanathan S, Harper C. Characterisation of GABAergic neurons within the human medial mamillary nucleus. Neuroscience 2004; 127: 365-372.

Dixon G, Harper C. No evidence for selective GABAergic interneuron deficits in the anterior thalamic complex of patients with schizophrenia.Progress in Neuropsychopharmacology and Biological Psychiatry 2004; 28: 1045-1051.

Karl T, Lin S, Schwarzer C, Sainsbury A, Couzens M, Wittman W, Boey D, von Horsten S, Herzog H. Y1 receptors regulate aggressive behaviour via modulating serotonin pathways. Proceedings of the National Academy of Sciences 2004; 101: 12742-12747.

Kent A, Fox A, Michie P, Jablensky A. Differential impairment of working memory performance in first-degree relatives of individuals with schizophrenia. Acta Neuropsychiatrica 2004; 16: 149-153.

Loughland C, Carr V, Lewin T, Barnard R, Chapman J, Walton J. Potential sampling and recruitment source impacts in schizophrenia research.Psychiatry Research 2004; 125: 117-127.

Loughland C, Williams L, Harris A. Visual scanpath dysfunction in first-degree relatives of schizophrenia probands: evidence for a vulnerability marker. Schizophrenia Research 2004; 67: 11-21.

Malhi G, Lagopoulos J, Sachdev P, Mitchell P, Ivanovski B, Parker G. Cognitive generation of affect in hypomania: an fMRI study. Bipolar Disorders 2004; 6: 271-285.

Malhi G, Lagopoulos J, Ward P, Kumari V, Mitchell P, Parker G, Teasdale J, Sachdev P. FMRI of cognitive generation of affect in bipolar depression. European Journal of Neuroscience 2004; 19: 741-754.

Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. Risk factors for transition to first episode psychosis among individuals with ‘at-risk mental states’. Schizophrenia Research 2004: 71: 227-237.

Rasser P, Johnston P, Ward P, Thompson P. Deformable Brodmann Area Atlas. Proceedings of the IEEE International Symposium on Biomedical Imaging: From Nano to Macro, 2004; 400-403.

Schleimer S, Hinton T, Dixon G, Johnston G. GABA transporters GAT-1 and GAT-3 in the human dorsolateral prefrontal cortex in schizophrenia.Neuropsychobiology 2004; 50: 226 – 230.

Tooney P, Chahl L. Neurons expressing calcium-binding proteins in the prefrontal cortex in schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 2004; 28: 273-278.

Williams L, Brown K, Das P, Brammer M, Boucsein B, Sokolov N, Olivieri G, Peduto A, Gordon E. The dynamics of cortico-amygdala and autonomic activity over the experimental time course of fear perception.Cognitive Brain Research 2004; 21: 114-123.

Williams L, Das P, Harris A, Liddell B, Brammer M, Skerrett D, Phillips M, David A, Peduto A, Gordon E. Dysregulation of arousal and amygdala-prefrontal systems in paranoid schizophrenia. American Journal of Psychiatry 2004; 161: 480-489.

Zavitsanou K. M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia (letter). Neuropsychopharmacology 2004; 29: 1585-1586.

Zavitsanou K, Garrick T, Huang X. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors in increased in the anterior cingulate cortex in schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 2004; 28: 355-360.

Zavitsanou K, Katsifis A, Mattner F, Huang X. Investigation of M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder and major depression disorder.Neuropsychopharmacology 2004; 29: 619-625.

Grants

Schizophrenia Research Institute Administered

Badcock J, Draganic D, Michie P, Ward P. Well-being in schizophrenia: the role of emotion in auditory hallucinations. A collaborative NISAD/CCRN study. Ron and Peggy Bell Foundation, 2004-2006 ($30,675).
Carr V, Draganic D, Harper C. The NSW Tissue Resource Centre and ‘Gift of Hope’ Tissue Donor Program. The Macquarie Bank Foundation, 2004-2007 ($75,000).

Carr V, Scott R, Tooney P, Loughland C, Draganic D. Schizophrenia DNA Bank. Australian Rotary Health Research Fund Project Grant, 2005 ($59,750).

Draganic D, Tooney P, Ward P. Analysis of gene expression in schizophrenia using genetic technology: NISAD PhD Scholarship for Schizophrenia Research. J S Love Trust, 2004-2005 ($20,000).

Loughland C. Face processing in schizophrenia and first degree relatives. NARSAD Young Investigator Award, 2004-2005 ($28,180).

McDonald D, Ward P, Schall U. Establishment of a NISAD research laboratory at the Psychological Assistance Service, Newcastle. The Mine Workers Trust, 2004 ($53,240).

Host Institution Administered

Bowden N. Altered expression of brain related genes in lymphocytes in schizophrenia. World Congress on Psychiatric Genetics Travel Grant, 2004 ($2,000).

Breakspear M. Young Mind in Psychiatry Award. American Psychiatric Association, 2003-2004 ($63,000).

Budd B. An integrated psychoacoustic and high-field fMRI study of auditory temporal processing dysfunction in schizophrenia. NHMRC New Investigator Grant, 2005-2007 ($302,250).

Budd B. Integrity of auditory temporal processing in the central auditory system in schizophrenia. University of Newcastle Early Career Researcher Project Grant, 2003-2004 ($11,500).

Budd B. Integrity of auditory temporal processing in the central auditory system in schizophrenia. University of Newcastle Research Management Committee Travel Grant, 2004 ($2,500).

Carr V, Ward P, Schall U, Baker A, Johnston P. A comparative structural and functional cerebral MRI study in first episode schizophrenia and long term cannabis users. NHMRC Project Grant, 2004-2006 ($365,000).

Cohen M, Johnston P, Schall U, Carr V. A comparative structural and functional cerebral MRI study of first episode schizophrenia and long-term cannabis use. University of Newcastle Project Grant, 2005 ($14,500).

Deng C. Dopamine and glutamate receptors in the prefrontal cortex in schizophrenia. University of Wollongong URC Small Grant, 2004 ($12,000).

Deng C. Muscarinic M1 and M2 receptors in the superior temporal gyrus of normal and schizophrenia subjects. University of Wollongong Early Career Grant, 2004-2005 ($2,000).

Green M. Face processing in social contexts. Macquarie University Research Development Grant, 2004-2005 ($20,000).

Huang X, Zavitsanou K, Deng C. ProgRes C10 digital microscope camera. NHMRC Equipment & University of Wollongong Research Committee Grants, 2004 ($5,000).

Loughland C, Cohen M, Johnston P, Carr V. Remediation of facial affect decoding and visual scanpath deficits in schizophrenia. University of Newcastle Project Grant, 2005 ($8,000).

Matsumoto I, Dedova I. Effects of chronic risperidone treatment on rat brain proteomics. Janssen-Cilag Japan, 2005 ($63,050).

McClean C, Harper C. National network of brain banks. NHMRC Enabling Grants, 2004-2009 ($2,000,000).

Michie P, Hunter M, Karayanidis F, Todd J, Budd B, Fulham R. Upgrade of ERP facilities in the Functional Neuroimaging Laboratory. Brain and Mental Health Research Program Grant, Hunter Medical Research Institute, 2004-2005 ($8,000).

Richards A. The contribution of contextual processing problems to reduced mismatch negativity in schizophrenia. EEG and Clinical Neuroscience Society Meeting Travel Award, 2004 ($1,500).

Schall U, Karayanidis F, Budd B, Johnston P. Functional neuroimaging of prepulse inhibition in schizophrenia and Parkinson’s disease. NHMRC Project Grant, 2005-2007 ($440,625).

Schall U, Karayanidis F, Johnston P. Functional neuroimaging and inhibitory brain processes in schizophrenia. University of Newcastle Project Grant, 2005 ($14,000).

Schall U, Michie P, Carr V, Johnston P, Karayanidis F, Todd J, Budd B, Cohen M. Research assistant for EEG recordings and neuropsychiatric assessments at the Psychological Assistance Service. Brain and Mental Health Research Program Grant, Hunter Medical Research Institute, 2004-2005 ($17,500).

Schall U, Michie P. Compatible 64-channel EEG recording system. University of Newcastle Research Infrastructure Block Grant, 2004 ($40,000).

Sim A, Aitken, Dunkley P, Rostas J, Dickson, Ashman, Smith, Burns, McCluskey, Tooney P, Ross F, Rose. Biacore 3000 – expansion of proteomics facility. ARC Lief Infrastructure Grant, 2004 ($187,340).

Solowij N. Functional magnetic resonance imaging indices of memory function in long-term cannabis users. Ian Potter Foundation Travel Grant, 2004 ($2,500).

Tooney P, Loughland C, Scott R, Carr V. Technical support for the Hunter DNA Bank for Schizophrenia and Allied Disorders. Brain and Mental Health Research Program, Hunter Medical Research Institute, 2004-2006 ($75,116).

Ward P. SynAmps2 EEG/ERP amplifier (64 channel). NHMRC Equipment Grant, 2004 ($30,000).

Weidenhofer J. Gene profiling in the amygdala in schizophrenia. World Congress on Psychiatric Genetics Travel Grant, 2004 ($2,000).

Williams L. Missing links: the cause and treatment of functional brain disconnections. Pharmacia Foundation Senior Research Fellowship, 2004-2008 ($983,500).

Zavitsanou K, Solowij N. Cannabinoid effects on brain chemistry and function relevant to psychosis. University of Wollongong URC Grant, 2004 ($12,300).

Research Degrees

Doctor of Philosophy

Dr Karin Aubrey, University of Sydney

Dr Patrick Johnston, University of Newcastle

Masters / Clinical Doctorate

Rachel Taylor, Macquarie University

Honours

Amanda Brown, University of Newcastle

Teresa du Bois, University of Wollongong

Kelly Skilbeck, University of Sydney

Summer Student Scholarships

Amanda Brown, University of Newcastle

Greg Peck, University of Newcastle

Kimberley Alexander, University of Sydney

Daniel Getts University of Sydney

Melissa Balkin, Garvan Institute of Medical Research

Teresa de Bois, University of Wollongong

Jennifer Waldron, Macquarie University

2005

Publications Grants Research Degrees

Publications

Aubrey K, Vandenberg R, Clements J. Dynamics of forward and reverse transport by the glial glycine transporter, GLYT1b. Biophysical Journal2005; 89: 1657-1668.

Badcock J, Maybery M. Common or distinct deficits for auditory and visual hallucinations? – Commentary. Behavioural and Brain Sciences2005; 28: 757-758.

Baker A, Bucci S, Lewin T, Richmond R, Carr V. Comparisons between psychosis samples with different patterns of substance use recruited for clinical and epidemiological studies. Psychiatry Research 2005; 134: 241-245.

Clunas N, Ward P. Auditory recovery cycle dysfunction in schizophrenia: a study using event related potentials. Psychiatry Research 2005, 136, 17-25.

Das P, Kemp A, Liddell B, Brown K, Olivieri G, Peduto T, Gordon E, Williams L. Pathways to fear perception: modulation of amygdala activity by thalamo-cortical systems. Neuroimage 2005; 26: 141-148.

Deng C, Huang XF. Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. Journal of Neuroscience Research 2005; 81: 883-890.

du Bois T. Schizophrenia, fats and lab rats. Rhizome 2005; 1: 17-24.

du Bois T, Bell W, Deng C, Huang XF. A high n-6 polyunsaturated fatty acid diet reduces muscarinic M2/M4 receptor binding in the rat brain. The Journal of Chemical Neuroanatomy 2005; 29: 282-288.

du Bois T, Deng C, Huang X. Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 2005; 29: 878-888.

Eyles D, Smith S, Kinobe R, Hewison M, McGrath J. Distribution of the vitamin D receptor and the 1a-hydroxylase in human brain. Journal of Chemical Neuroanatomy 2005; 29: 21-30.

Harper C, Matsumoto I. Ethanol and brain damage. Current Opinion in Pharmacology 2005; 5: 73-78.

Harris A, Brennan J, Anderson J, Taylor A, Sanbrook M, Fitzgerald D, Lucas S, Redoblado-Hodge A, Gomes L, Gordon E. The clinical profile of first episode psychosis in Western Sydney – Scope and general findings of the Western Sydney First Episode Psychosis Project. Australian and New Zealand Journal of Psychiatry 2005; 39: 36-43.

Ito M, Depaz I, Wilce P, Suzuki T, Niwa S, Matsumoto I. Expression of human neuronal protein 22, a novel cytoskeleton-associated protein in the prefrontal cortex, anterior cingulate cortex and hippocampus of schizophrenic brain: an immunohistochemical study. Neuroscience Letters 2005; 378: 125-130.

Johnston P, Stojanov W, Devir H, Schall U. Functional MRI of facial emotion recognition deficits in schizophrenia and their electrophysiological correlates. European Journal of Neuroscience 2005; 22: 1221-1232.

Lagopoulos J, Malhi G, Shnier R. A fibre-optic system for recording skin conductance in the scanner. Behaviour Research Methods 2005; 37: 657-664.

Liddell B, Brown K, Kemp A, Barton M, Das P, Peduto A, Gordon E, Williams L. A direct brainstem-amygdala-cortical ‘alarm’ system for subliminal signals of fear. Neuroimage 2005; 24: 235-243.

Loughland C. Depressed and Anxious: The Dialectical Behaviour Therapy Workbook for Overcoming Depression and Anxiety (book review). Drug and Alcohol Review 2005; 24: 572-573.

McKay R, Langdon R, Coltheart M. Paranoia, persecutory delusions and attributional biases. Psychiatry Research 2005; 233: 233-245.

Newell K, Zavitsanou K, Huang XF. Ionotropic glutamate receptor binding in the posterior cingulate cortex in schizophrenia patients. NeuroReport2005; 16: 1363-1367.

Newson P, Lynch-Frame A, Roach R, Bennett S, Carr V, Chahl L. Intrinsic sensory deprivation induced by neonatal capsaicin treatment induces changes in rat brain and behaviour of possible relevance to schizophrenia. British Journal of Pharmacology 2005; 146: 408-418.

Nicholson R, Karayanidis F, Poboka D, Heathcote A, Michie P. Electrophysiological components associated with anticipatory task-switching processes. Psychophysiology 2005; 42: 540-554.

Rasser P, Johnston P, Lagopoulos J, Ward P, Schall U, Thienel R, Bender S, Toga A, Thompson P. Functional MRI BOLD response to Tower of London performance of first-episode schizophrenia patients using cortical pattern matching. Neuroimage 2005; 26: 941-951.

Russell T, Reynaud E, Herba C, Morris R, Corcoran R. Do you see what I see? Interpretations of intentional movement in schizophrenia.Schizophrenia Research 2005; 81: 101-111.

Sachdev P, Loo C, Mitchell P, Malhi G. Transcranial magnetic stimulation for the deficit syndrome of schizophrenia: a pilot investigation. Psychiatry and Clinical Neurosciences 2005; 59: 354-357.

Solowij N. EMCDDA Insights 6: An overview of cannabis potency in Europe (Book review). Drug and Alcohol Review 2005; 24: 291-293.

Startup M, Startup S. On two kinds of delusion of reference. Psychiatry Research 2005; 137; 87-92.

Teubner M, Nixon J, Rasser P, Bottema M, Clark R. Source localisation in a real human head. Brain Topography 2005; 17: 197-205.

Tooney P, Anderson W, Lynch-Frame A, Chahl L. The effects of haloperidol treatment on the distribution of NK1 receptor immunoreactive neurons in the guinea pig brain. Neuroscience Letters 2005; 383: 155-159.

Schleimer S, Johnston G, Henderson J. Novel oral drug administration in an animal model of neuroleptic therapy. Journal of Neuroscience Methods2005: 146: 159-164.

Whitford T, Farrow T, Gomes L, Brennan J, Harris A, Williams L. Grey matter deficits and symptom profile in first-episode schizophrenia.Psychiatry Research: Neuroimaging 2005; 139: 229-238.

Williams L, Das P, Liddell B, Olivieri G, Peduto A, Brammer M, Gordon E. BOLD, sweat and fears: fMRI and skin conductance distinguish facial fear signals. Neuroreport 2005; 16: 49-52.

Wright M, Harmon K, Bowman J, Lewin T, Carr V. Caring for depressed patients in rural communities: general practitioners, attitudes, needs and relationships with mental health services. Australian Journal of Rural Health 2005; 13: 21-27.

Zavitsanou K, Katsifis A, Yu Y, Huang X. M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Research Bulletin 2005; 65: 397-403.

Grants

Schizophrenia Research Institute Administered

Carr V, Schall U, Scott R, Jablensky A, Mowry B, Michie P, Catts S. Australian Schizophrenia Research Bank. NHMRC Enabling Grant, 2006 – 2010 ($1,750,000).

Carr V, Scott R, Tooney P, Loughland C, Draganic D. Schizophrenia DNA Bank. Australian Rotary Health Research Fund Project Grant, 2006 ($59,750).

Dedova I. Effects of chronic haloperidol treatment on proteomic profiles in the rat striatum. Australian Neuroscience Society Travel Award, 2005 ($500).

Draganic D, Carr V. The neural pathophysiology of the posterior cingulate cortex in schizophrenia: The St George Foundation Scholarship for Schizophrenia Research. The St George Foundation, 2005 ($10,000).

Schofield P, Draganic D, Carr V. Linking basic and clinical research to understand the causes of schizophrenia (PPI equipment). The Alma Hazel Eddy Trust & Baxter Charitable Foundation, 2005 ($19,000).

Host Institution Administered

Aitken R, McLaughlin E, Lewis P, Griffith R, Rose R, Patrick J, McCurdy D, McCluskey A, Von Nagy-Felsobuki E, Dunkley P, Dickson P, Rostas J, Ashman L, Burns G, Foster P, Gibson P, Smith R, Sim A, Tooney P, Ross F. The University of Newcastle Advanced Proteomics Facility. ARC Linkage Infrastructure Equipment & Facilities Grant, 2005 ($207,189).

Catts S, Willcox D. A constituency building project in support of an Australian Psychosis Research Network. The Myer Foundation, 2005-2006 ($80,000).

Chetcuti A, Schofield P. Analysis of gene expression in a mouse model of schizophrenia. Rebecca Cooper Foundation, 2005-2006 ($9,368).

Deng C. Pathological alterations in glutamate receptors in the superior temporal gyrus in schizophrenia. University of Wollongong Health and Behavioural Sciences Faculty Small Grant, 2005-2006 ($5,000).

Deng C. Noldus EthoVision Video Tracking System for automation of behavioural experiments. Clive and Vera Ramaciotti Foundation Equipment Grant, 2005, ($25,000).

Deng C. Schizophrenia and muscarinic receptor gene expression in the superior temporal gyrus. University of Wollongong URC Small Grant, 2005-2006 ($18,954).

Deng C, Zavisanou K, Huang XF, Katsifis A, Nguyen V. Phencyclidine induced apoptosis in the brain: implications for schizophrenia. AINSE Grant, 2005-2006 ($21,610).

Harper C, Green A, Garrick T. Using our Brains TDP, analysis of cognitive effects in drinkers and non drinkers – Australian normative data. Australian Brewer’s Foundation, 2005 ($32,500).

Henskens F, Johnston P, Rasser P, Ward P, Schall U, Thompson P, Michie P, Carr V. Development of a software grid for data sharing associated with the NISAD Virtual Brain Bank. ARC E Research Special Initiatives Grant, 2005-2006, ($95,254).

Huang XF. Neurochemistry of the ‘psychosis circuit’ in schizophrenia. University of Wollongong Health and Behavioural Sciences Faculty Seeding Grant, 2005 ($5,000).

Karl T, Herzog H. Environmental and genetic background effects on the behavioural phenotype of a schizophrenia-related Nrg1 knockout model. The Rebecca Cooper Medical Research Foundation, 2005 ($16,000).

Kelly B, Stain H, Carr V, Beard J, Fragar L, Lewin T. Mental health and wellbeing in rural and remote NSW. NHMRC Project Grant, 2006-2008 ($717,750).

Matsumoto I, Draganic D, Sivagnanasundaram S, Dedova I, Carr V. ElectrophoretIQ3TM Electrophoresis Platform for Schizophrenia Research. Cecilia Kilkeary Foundation, 2005 ($9,000).

Matsumoto I. Brain bank and donor program for biomedical research into schizophrenia and alcohol-related disorders. NSW Ministry for Science and Medical Research Biofirst Award Extension, 2006 ($110,000).

Meyer B, Solowij N, Monterrubio S. A study of stress, cannabis use and fatty acids in schizophrenia. University of Wollongong Faculty of Health and Behavioural Sciences Small Research Grant, 2005-2006 ($5,000).

Newell K. Increased NMDA receptor density in the posterior cingulate cortex in schizophrenia: selective alterations in ionotropic glutamate receptors in the posterior cingulate cortex in schizophrenia. University of Wollongong Travel Grant, 2005 ($1,000).

Startup M, Carr V, Baker A, Schall U, Stain H. The effectiveness of cognitive behaviour therapy for young people at risk of serious mental disorders. NHMRC Project Grant, 2006-2008 ($606,475).

Tan YY. Adrenoceptors regulation in human prefrontal cortex – possible mechanism for cognitive dysfunction in schizophrenia. University of Wollongong Early Career Researcher Grant, 2005 ($2,000).

Tan YY. Effects of acute and chronic antipsychotic treatment on brain adrenoceptors and intracellular signalling proteins. University of Wollongong Health and Behavioural Sciences Faculty Small Grant, 2005-2006 ($5,000).

Research Degrees

Masters / Clinical Doctorate

Holly Devir, University of Newcastle

Honours

Simon Howell, University of Sydney

Danielle Clark, University of Sydney

Wan-Yi Ng, University of Sydney

Elizabeth O’Brien, University of Sydney

Jenn O’Reilly, University of Sydney

Madeleine Hinwood, University of Newcastle

Gabrielle McQueen, University of Newcastle

Siobahn Quinn, University of Newcastle

Natalie Potter, University of Wollongong

Summer Student Scholarships

Madeleine Hinwood, University of Newcastle

Natalie Beveridge, University of Newcastle

Kathleen Khoo, University of Newcastle

Gabrielle McQueen, University of Newcastle

Kevin Aquino, University of Sydney

Danielle Clark, University of Sydney

Kelly Skilbeck, University of Sydney

2006

Publications Grants Research Degrees

Publications

Andresen R, Caputi P, Oades L. Stages of recovery instrument: development of a measure of recovery from serious mental illness.Australian and New Zealand Journal of Psychiatry 2006; 40: 972-980.

Azizi L, Garrick T, Harper C. Brain donation for research: strong support in Australia. Journal of Clinical Neuroscience 2006; 13: 449-452.

Baker A, Bucci S, Lewin T, Kay-Lambkin F, Constable P, Carr V. Cognitive-behavioural therapy for substance use disorders among people with psychotic disorders: randomised controlled trial. British Journal of Psychiatry 2006; 188: 439-448.

Baker A, Richmond R, Haile M, Lewin T, Carr V, Taylor R, Jansons S, Wilhelm K. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. American Journal of Psychiatry 2006; 163: 1934-1942.

Blair I, Chetcuti A, Badenhop R, Scimone A, Moses M, Adams L, Craddock N, Green E, Kirov G, Owen M, Kwok J, Donald JK, Mitchell P, Schofield P. Positional cloning, association analysis, and expression studies provide convergent evidence that the cadherin gene FAT contains a bipolar disorder susceptibility allele. Molecular Psychiatry 2006; 11: 372-383.

Boey D, Lin S, Karl T, Baldock P, Lee N, Enriquez R, Couzens M, Slack K, Dallmann R, Sainsbury A, Herzog H. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia2006; 49: 1360-1370.

Bowden N, Weidenhofer J, Scott R, Schall U, Todd J, Michie P, Tooney P. Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophrenia Research 2006; 82: 175-183.

Breakspear M, Bullmore E, Aquino K, Das P, Williams L. The multiscale character of evoked cortical activity. Neuroimage 2006; 30: 1230-1242.

Carr V, Lewin T, Neil A. What is the value of treating schizophrenia?Australian and New Zealand Journal of Psychiatry 2006; 40: 963-971.

Chahl L. Tachykinins and neuropsychiatric disorders. Current Drug Targets 2006; 7: 993-1003.

Chetcuti A, Adams L, Mitchell P, Schofield P. Altered gene expression in mice treated with the mood stabilizer sodium valproate. International Journal of Neuropsychopharmacology 2006; 9: 267-276.

Clark D, Dedova I, Cordwell S, Matsumoto I. A proteome analysis of the anterior cingulate cortex grey matter in schizophrenia. Molecular Psychiatry 2006; 11: 459-470.

Dallmann R, Steinlechner S, H�rsten S, Karl T. Stress-induced hyperthermia in the rat: comparison of classical and novel recording methods. Laboratory Animals 2006; 40: 186-193.

Deng C, Huang X>. Increased density of GABA-A receptors in the superior temporal gyrus in schizophrenia. Experimental Brain Research2006; 168: 587-590.

du Bois T, Deng C, Bell W, Huang XF. Fatty acids differentially affect serotonin receptor and transporter binding in the rat brain. Neuroscience2006; 139: 1397-1403.

Garrick T, Howell S, Terwee P, Redenbach J, Blake H, Harper C. Brain donation for research – who donates and why? Journal of Clinical Neuroscience 2006; 13: 524-528.

Garrick T, North A, Glaw X, Harper C. The diagnosis is critical for psychiatric brain banks: an inter-rater reliability study (letter). Australian and New Zealand Journal of Psychiatry 2006; 40: 606-607.

Huang XF, Deng C, Zavitsanou K. Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine and haloperidol administration in rats. Neuropeptides 2006; 40: 213-219.

Huang XF, Han M, Huang X, Zavitsanou K, Deng C. Olanzapine differentially affects 5-HT2A and 5-HT2C receptor mRNA expression in the rat brain. Behavioural Brain Research 2006; 171: 355-362.

Ide M, Ohnishi T, Murayama M, Matsumoto I, Yamada K, Iwayama Y, Dedova I, Toyota T, Asada T, Takashima A, Yoshikawa T. Failure to support a genetic contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia. Journal of Neurochemistry 2006; 99: 277-287.

Iwazaki T, McGregor I, Matsumoto I. Protein expression profile in the striatum of acute methamphetamine-treated rats. Brain Research 2006; 1097: 19-25.

Johnston P, Devir H, Karayanidis F. Facial emotion processing in schizophrenia: no evidence for a negative emotion specific deficit using a differential deficit design. Psychiatry Research 2006; 143: 51-61.

Kapoor R, Lim K, Chang A, Garrick T, Kapoor V. Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, D-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1). Brain Research 2006; 23: 205-210.

Karayanidis F, Nicholson R, Meem L, Michie P, Schall U. Switching between univalent task-sets in schizophrenia: ERP evidence of an anticipatory task-set reconfiguration deficit. Clinical Neurophysiology2006; 117: 2172-2190.

Karl T, Burne T, Herzog H. Effect of Y1 receptor deficiency on motor activity, exploration, and anxiety. Behavioural Brain Research 2006; 167: 87-93.

Karl T, Duffy L, O’Brien E, Matsumoto I, Dedova I. Behavioural effects of chronic haloperidol and risperidone treatment in rats. Behavioural Brain Research 2006; 171: 286-294.

Lagopoulos J, Gordon E, Ward P. Differential BOLD responses to auditory target stimuli associated with a skin conductance response. Acta Neuropsychiatrica 2006; 18: 105-114.

Langdon R, Coltheart M, Ward P. Empathetic perspective-taking is impaired in schizophrenia: evidence from a study of emotion attribution and theory of mind. Cognitive Neuropsychiatry 2006; 11: 133-155.

Langdon R, Corner T, McLaren J, Coltheart M, Ward P. Attentional orienting triggered by gaze in schizophrenia. Neuropsychologia 2006; 44: 417-429.

Langdon R, Corner T, McLaren J, Ward P, Coltheart M. Externalizing and personalizing biases in persecutory delusions: the relationship with insights and theory of mind. Behaviour Research and Therapy 2006; 44: 699-713.

Lin E, Lee N, Slack K, Karl T, Duffy L, O’Brien E, Matsumoto I, Dedova I, Herzog H, Sainsbury A. Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. Neuropharmacology 2006; 51: 1129-1136.

McKay R, Langdon R, Coltheart M. Need for closure, jumping to conclusions, and decisiveness in delusion-prone individuals. Journal of Nervous & Mental Disease 2006; 194: 422-426.

McKay R, Langdon R, Coltheart M. The Persecutory Ideation Questionnaire. Journal of Nervous and Mental Disease 2006; 194: 628-631.

Monterrubio S, Solowij N. Chronic stress and adaptation (letter).American Journal of Psychiatry 2006; 163: 553.

Monterrubio S, Solowij N, Meyer B, Turner N. Fatty acid relationships in former cannabis users with schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 2006; 30: 280-285.

Newell K, Deng C, Huang XF. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Experimental Brain Research 2006; 172: 556-560.

Nicholson R, Karayanidis F, Bumak E, Poboka D, Michie P. ERPs dissociate the effects of switching task-sets and task-cues. Brain Research 2006; 1095: 107-123.

Nicholson R, Karayanidis F, Davies A, Michie P. Components of task set reconfiguration: differential effects of ‘switch-to’ and ‘switch-away’ cues.Brain Research 2006; 1121: 160-176.

O’Brien E, Dedova I, Duffy L, Karl T, Matsumoto I. Effects of chronic risperidone treatment on the striatal protein profiles in rats. Brain Research 2006; 1113: 24-32.

Paulik G, Badcock J, Maybery M. The multifactorial structure of the predisposition to hallucinate and associations with anxiety, depression and stress. Personality and Individual Differences 2006; 41: 1067-1076.

Rossell S, David A. Are semantic deficits in schizophrenia due to problems with access or storage? Schizophrenia Research 2006; 82: 121-134.

Russell T, Chu E, Phillips M. A pilot study to investigate the effectiveness of emotion recognition remediation in schizophrenia using the Micro-Expression Training Tool. British Journal of Clinical Psychology 2006; 45: 579-583.

Sainsbury A, Bergen H, Boey D, Bamming D, Cooney G, Lin S, Couzens M, Stroth N, Lee N, Lindner D, Singewald N, Karl T, Duffy L, Enriquez R, Slack K, Sperk G, Herzog H. Y2 / Y4 receptor double knockout protects against obesity due to a high-fat diet or Y1 receptor deficiency in mice.Diabetes 2006; 55: 19-26.

Silverstein S, Uhlhass P, Essex B, Halpin S, Schall U, Carr V. Perceptual organization deficits in first episode schizophrenia and ultra-high risk states. Schizophrenia Research 2006; 83: 41-52.

Solowij N, Monterrubio S. Cognitive and neuropsychiatric consequences of endocannabinoid signaling dysfunction (letter).Neuropsychopharmacology 2006; 31: 471-472.

Weidenhofer J, Bowden N, Scott R, Tooney P. Altered gene expression in the amygdala in schizophrenia:Up-regulation of genes located in the cytomatrix active zone. Molecular and Cellular Neuroscience 2006; 31: 243-250.

Weidenhofer J, Yip J, Zavitsanou K, Huang XF, Chahl L, Tooney P. Immunohistochemical localisation of the NK1 receptor in the human amygdala: preliminary investigation in schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 2006; 30: 1313-1321.

Wheeler D, Dixon G, Harper C. No differences in calcium-binding protein immunoreactivity in the posterior cingulate and visual cortex: schizophrenia and normal controls. Progress in Neuropsychopharmacology and Biological Psychiatry 2006; 30: 630-639.

Whitford T, Grieve S, Farrow T, Gomes L, Brennan J, Harris A, Gordon E, Williams L. Progressive grey matter atrophy over the first 2-3 years of illness in first-episode schizophrenia: A tensor-based morphometry study.Neuroimage 2006; 32: 511-519.

Williams L, Das P, Liddell B, Kemp A, Rennie C, Gordon E. Mode of functional connectivity in amygdala pathways dissociates level of awareness for innate signals of fear. Journal of Neuroscience 2006; 26: 9264-9271.

Grants

Schizophrenia Research Institute Administered

Carr V, Loughland C, Schall U, Scott R, Jablensky A, Mowry B, Michie P, Catts S, Henskens F, Pantelis C. Clinical and neuropsychological assessment instruments for the Australian Schizophrenia Research Bank. NHMRC Equipment Grant, 2006 ($7,592).

Karl T. Conditional NPY Y1 receptor deficient mice – a potential new animal model for schizophrenia? NARSAD Young Investigator Award, 2006-2007 ($81,000).

Willcox D, Draganic D, Loughland C, Carr V. Australian Schizophrenia Research Bank. The Pratt Foundation, 2007-2012 ($1,400,000).

Host Institution Administered

Arnold J. An animal model of genetic vulnerability to cannabis-induced psychosis. Clive and Vera Ramaciotti Establishment Grant, 2006 ($29,000).

Cairns M, Tooney P, Scott R. Investigation of miRNA’s in schizophrenia. University of Newcastle Pilot Grant, 2006-2007 ($20,000).

Chahl L, Zavitsanou K. Receptor changes in brain tissue of rats treated as neonates with capsaicin – testing a putative new animal model of schizophrenia. Australian Institute of Nuclear Science and Engineering Grant, 2006-2007 ($18,540).

Deng C. The effect of antipsychotic drugs on the density of neuropeptide Y receptors in the brain stem of rats. University of Wollongong Health & Behavioural Science Small Grant, 2006 ($5,000).

Deng C. Antipsychotic drug-induced weight gain and expression of cholecystokinin receptors in the brainstem of rats. University of Wollongong Health & Behavioural Science Small Grant, 2007 ($12,500).

du Bois T. Brain development disruption from PCP causes behavioural deficits in the forced swin test in later life. Australasian Schizophrenia Conference Travel Award, 2006 ($500).

Green M. Remediation of facial emotion perception in psychotic disorders. NARSAD Young Investigator Award, 2006 ($41,000).

Huang XF. NMDA receptor hypofunction during perinatal brain development: implications for schizophrenia. University of Wollongong Health & Behavioural Science Seeding Grant, 2006 ($5,000).

Jin J, Aisbett J, Schall U, Luo S, Rasser P, Regan B. Improving Alzheimer’s disease diagnosis by analysing brain tissue using pathology/radiology informatics. CSIRO Flagship Project, 2006-2007 ($110,000).

Karayanidis F, Michie P. The spatial and temporal dynamics of motor and cognitive inhibition in schizophrenia: An fMRI and ERP study. Hunter Medical Research Institute Grant, 2006 ($12,600).

Loughland C. Eyelink II Eye Tracker Equipment. University of Newcastle School of Medicine & Public Health Research Infrastructure Grant, 2006 ($70,000).

Michie P, Schall U, Stain H, Carr V. Predictors of transition to psychosis in an ‘at-risk’ population: a pilot study. University of Newcastle Strategic Pilot Grant, 2006-2008 ($20,000).

Schall U, Campbell L. An investigation of the precursors of psychosis in 22q11.2 deletion syndrome. Hunter Medical Research Institute Postdoctoral Fellowship, 2006-2009 ($300,000).

Solowij N. Effects of comorbid cannabis use and schizophrenia on memory, apathy and executive functioning. University of Wollongong Health & Behavioural Science Small Grant, 2006 ($4,000).

Karl T. NPY Y1 and Y2 receptor mediated aggression. DFG Postdoctoral Fellowship, 2006 ($50,000).

Karl T. Effects of NPY and its Y1 receptor on stress-induced motor activity and anxiety. DFG Travel Grant, 2006 ($4,000).

Research Degrees

Doctor of Philosophy

Dr Nikola Bowden, University of Newcastle

Dr Rebecca Nicholson, University of Newcastle

Dr Sonja Schleimer, University of Sydney

Dr Judith Weidenhofer, University of Newcastle

Masters / Clinical Doctorate

Adele Sedgman, University of Newcastle

Honours

Natalie Beveridge, University of Newcastle

Adam Carroll, University of Newcastle

David Van der Weyde, University of Newcastle

Julijana Eftimovska, University of Wollongong

Ching-Wen Hsu, University of Wollongong

Katrina Weston, University of Wollongong

Nicole Caixeiro, University of Sydney

Maryam Nesvaderani, University of Sydney

Summer Student Scholarships

Julijana Eftimovska, University of Wollongong

Ching-Wen Hsu, University of Wollongong

Katrina Weston, University of Wollongong

David Van der Weyde, University of Newcastle

Caroline Beattie, Macquarie University

Nicole Caixeiro, University of Sydney

Maryam Nesvaderani, University of Sydney

Mikail Rubinov, University of New South Wales

2007

Publications Grants Research Degrees

Publications

Alexander K, Dedova I, Harper C, Matsumoto I. Proteome analysis of the dorsolateral prefrontal region from healthy individuals. Neurochemistry International 2007; 51:433-439.

Baker A, Richmond R, Haile M, Lewin T, Carr V, Taylor R, Constable P, Jansons S, Wilhelm K, Moeller-Saxone. Characteristics of smokers with a psychotic illness and implications for smoking interventions. Psychiatry Research 2007; 150: 141-152.

Bhindi R, Fahmy R, Lowe H, Chesterman C, Dass C, Cairns M, Saravolac E, Sun L-Q, Khachigian L. Brothers in arms: DNAzymes, siRNA and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. American Journal of Pathology 2007; 171 :1079-1088.

Boucher A, Arnold J, Duffy L, Schofield P, Micheau J, Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of D9-tetrahydrocannabinol. Psychopharmacology 2007; 192: 325-336.

Boucher A, Hunt G, Karl T, Micheau J, McGregor I, Arnold J. Heterozygous neuregulin 1 mice display greater baseline and 9-tetrahydrocannabinol-induced c-Fos expression. Neuroscience 2007; 149:861-870.

Bowden N, Scott R, Tooney P. Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia. Schizophrenia Research 2007; 89: 165-168.

Bradley A, Baker A, Lewin T. Group intervention for coexisting psychosis and substance use disorders in rural Australia: outcomes over 3 years.Australian and New Zealand Journal of Psychiatry 2007; 41:501-508.

Campbell L, Hughes M, Budd T, Cooper G, Fulham W, Karavanidis F, Hanlon MC, Stojanov W, Johnston P, Case V, Schall U. Primary and secondary neural networks of auditory prepulse inhibition: A functional magnetic resonance imaging study of sensorimotor gating of the human acoustic startle response. European Journal of Neuroscience 2007, 26: 2327-2333.

Chahl L. TRP’s: Links to schizophrenia? Biochimica et Biophysica Acta2007; 1772: 968-977.

Clark D, Dedova I, Cordwell S, Matsumoto I. Altered proteins of the anterior cingulate cortex white matter proteome in schizophrenia.Proteomics – Clinical Applications 2007; 1: 157-166.

Das P, Kemp A, Flynn G, Harris A, Liddell B, Whitford T, Peduto A, Gordon E, Williams L. Functional disconnections in the direct and indirect amygdala pathways for fear processing in schizophrenia. Schizophrenia Research 2007; 90: 284-294.

Deng C, Han M, Huang XF. No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. Neuroscience Bulletin 2007; 23: 341-347.

Deng C, Weston-Green K, Han M, Huang XF. Olanzapine treatment decreases the density of muscarinic M2 receptors in the dorsal vagal complex in rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2007; 31: 915-920.

Draganic D, Catts S, Carr V. The Neuroscience Institute of Schizophrenia and Allied Disorders (NISAD): 10 years of Australia’s first ‘virtual research institute’. Australian and New Zealand Journal of Psychiatry 2007; 41: 78-88.

du Bois T, Huang XF. Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia. Brain Research Reviews 2007; 53: 260-270.

Felmingham K, Kemp A, Williams L, Das P, Hughes G, Peduto A, Bryant R. Changes in anterior cingulate and amygdala after cognitive behavior therapy of posttraumatic stress disorder. Psychological Science 2007; 18: 127-129.

Ferker N, Wagner L, Wolf R, Heiser U, Hoffmann T, Rahfeld J, Schade J, Karl T, Naim H, Alfalah M, Demuth H, Von Horsten S. Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologs of dipeptidyl peptidase 4. Peptides 2007; 28: 257-268.

Green M, Waldron J, Coltheart M. Emotional context processing is impaired in schizophrenia. Cognitive Neuropsychiatry 2007; 12: 259-280.

Henry J, Green M, de Lucia A, Restuccia C, McDonald S, O’Donnell M. Emotion dysregulation in schizophrenia: Reduced amplification of emotional expression is associated with emotional blunting.Schizophrenia Research 2007; 95: 197-204.

Henry J, Rendell P, Kliegel M, Altgassen M. Prospective memory in schizophrenia: Primary or secondary impairment? Schizophrenia Research 2007; 95: 179-185.

Huang, XF, Tan YY, Huang X, Wang Q. Effect of chronic treatment with clozapine and haloperidol on 5-HT2A and 2C receptor mRNA expression in the rat brain. Neuroscience Research 2007; 59: 314-321.

Iwazaki T, McGregor I, Matsumoto I. Protein expression profile in the striatum of rats with methamphetamine-induced behavioral sensitization.Proteomics 2007; 7: 1131-1139.

Karl T, Duffy L, Scimone A, Harvey R, Schofield P. Altered motor activity, exploration, and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behaviour2007; 6: 677-687.

Karl T, Herzog H. Behavioural profiling of NPY in aggression and neuropsychiatric diseases. Peptides 2007; 28: 326-333.

Kemp A, Felmingham K, Das P, Hughes G, Peduto A, Bryant R, Williams L. Influence of comorbid depression on fear in posttraumatic stress disorder: An fMRI study. Psychiatry Research: Neuroimaging 2007; 155: 265-269.

Loughland C, Lewin T, Carr V, Sheedy J, Harris A. RBANS neuropsychological profiles within schizophrenia samples recruited from non-clinical settings. Schizophrenia Research 2007; 89: 232-242.

Malhi G, Lagopoulos J, Owen A, Ivanovski B, Shnier R, Sachdev P. Reduced activation to implicit affect induction in euthymic bipolar patients: an fMRI study. Journal of Affective Disorders 2007; 97: 109-122.

Matthews N, Todd J, Budd B, Cooper G, Michie P. Auditory lateralization in schizophrenia – Mismatch negativity and behavioral evidence of a selective impairment in encoding interaural time cues. Clinical Neurophysiology 2007; 118: 833-844.

McKay R, Langdon R, Coltheart M. The defensive function of persecutory delusions: an investigation using the implicit association test. Cognitive Neuropsychiatry 2007; 12: 1-24.

McKay R, Langdon R, Coltheart M. Jumping to delusions? Paranoia, probabilistic reasoning and need for closure. Cognitive Neuropsychiatry2007; 12: 362-376.

Newell K, Zavitsanou K, Huang XF. Opposing short and long-term effects on muscarinic M1/4 receptor binding following chronic phencyclidine treatment. Journal of Neuroscience Research 2007; 85: 1358-1363.

Newell K, Zavitsanou K, Huang XF. Short and long term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment. Journal of Neural Transmission 2007; 114: 995-1001.

Newell K, Zavitsanou K, Kum Jew S, Huang XF. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 2007; 31: 225-233.

Paulik G, Badcock J, Maybery M. Impaired intentional inhibition in individuals predisposed to hallucinations. Cognitive Neuropsychiatry 2007; 12: 457-470.

Rahardjo G, Huang XF, Tan YY, Deng C. Decreased plasma peptide YY accompanied by an elevated peptide YY and Y2 receptor binding densities in the medulla oblongata of diet-induced obese mice.Endocrinology 2007; 148: 4704-4710.

Russell T, Reynaud E, Kucharska-Pietura K, Ecker C, Benson P, Zelaya F, Giampietro V, Brammer M, David A, Phillips M. Neural responses to dynamic expressions of fear in schizophrenia. Neuropsychologia 2007; 45: 107-123.

Sainsbury A, Lin S, McNamara K, Slack K, Enriquez R, Lee N, Boey D, Smythe G, Schwarzer C, Baldock P, Karl T, Lin EJ, Couzens M, Herzog H. Dynorphin knockout reduces fat mass and increases weight loss during fasting in mice. Molecular Endocrinology 2007; 21: 1722-1735.

Sivagnanasundaram S, Cordwell S, Matsumoto I. Abnormal pathways in the genu of the corpus callosum in schizophrenia pathogenesis: a proteome study. Proteomics: Clinical application 2007; 1: 1291-1305.

Sivagnanasundaram S, Fletcher D, Hubank M, Lindsay E, Baldini A, Skuse D, Scambler P. Differential gene expression in the hippocampus of the Df1/+ mice: a model for 22q11.2 deletion syndrome and schizophrenia. Brain Research 2007; 1139: 48-59.

Schizophrenia Research 2007; 90: 76-80.

Solowij N, Michie P. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? Journal of Psychiatry and Neuroscience 2007; 32: 30-52.

Wheeler D, Harper C. Localised reductions in gyrification in the posterior cingulate: schizophrenia and controls. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2007; 31: 319-327.

Whitford T, Farrow T, Rennie C, Grieve S, Gomes L, Brennan J, Harris A, Williams L. Longitudinal changes in neuroanatomy and neural activity in early schizophrenia. Neuroreport 2007; 18: 435-439.

Whitford T, Grieve S, Farrow T, Gomes L, Brennan J, Harris A, Gordon E, Williams L. Volumetric white matter abnormalities in first-episode schizophrenia: a longitudinal, tensor-based morphometry study. American Journal of Psychiatry 2007; 164: 1082-1089.

Williams L, Das P, Liddell B, Olivieri G, Peduto A, Harris A. Fronto-limbic and autonomic disjunctions to negative emotion distinguish schizophrenia subtypes. Psychiatry Research: Neuroimaging 2007; 155: 29-44.

Yucel M, Lubman D, Solowij N, Brewer W. Understanding drug addiction: a neuropsychological perspective. Australian and New Zealand Journal of Psychiatry 2007; 41: 957-968.

Zavitsanou K, Nguyen K, Han M, Katsifis A, Huang XF. Effects of typical and atypical antipsychotic drugs on rat brain muscarinic receptors.Neurochemical Research 2007; 32: 525-532.

Grants

Schizophrenia Research Institute Administered

Carr V, Draganic D. The Australian Schizophrenia Research Bank. Perpetual Trustees (Patrick Brennan Trust and Baxter Charitable Trust), 2007-2008 ($50,000).

Carr V, Draganic D. Identification of schizophrenia risk factors in Australian children. Janssen-Cilag, 2007-2008 ($75,000).

Carr V, Draganic D. The Macquarie Bank Foundation Chair of Schizophrenia Research. The Macquarie Bank Foundation, 2007-2012 ($1,375,000).

Carr V, Loughland C, Schall U, Scott R, Jablensky A, Mowry B, Michie P, Catts S, Henskens F, Pantelis C. Siemens diffusion tensor imaging acquisition software for Magnetom Avanto. NHMRC Equipment Grant, 2007 ($7,640).

Draganic D, Carr V. Well-being in schizophrenia: the role of emotion in auditory hallucinations. A collaborative SRI/CCRN study. Ron and Peggy Bell Foundation, 2007-2008 ($10,000).

Draganic D, Carr V. Schizophrenia Research Institute and ANSTO Postdoctoral Fellowship in Schizophrenia Research. ANSTO, 2007-2010 ($121,400).

Dedova I, Garrick T, Matsumoto I, Harper C. Identifying the causes of antipsychotic drug-induced parkinsonism: in search of better treatments for schizophrenia. Rebecca Cooper Medical Research Foundation, 2007 ($10,500).

Karl T. The role of major components of cannabis (?9-tetrahydrocannabinol and cannabidiol) in an Nrg1 animal model of genetic vulnerability to schizophrenia. Ramaciotti Establishment Gift, 2008 ($28,285).

Karl T, Arnold J, Huang XF, McGregor I. The role of cannabis in an Nrg1 animal model of genetic vulnerability to schizophrenia. NHMRC Project Grant, 2008-2010 ($437,125).

Host Institution Administered

Cairns M. Post transcriptional gene silencing in schizophrenia. NARSAD Young Investigator Award, 2007-2008 ($73,000).

Campbell L. Functional brain imaging of prepulse inhibition in 22q11.2 deletion syndrome (22qDS). NHMRC Australian Training Research Fellowship (part-time), 2007-2010 ($134,500).

Chetcuti A, Schofield P. Characterisation of schizophrenia associated genes using a model of antipsychotic drug action. UNSW Early Career Researcher Grant, 2007 ($32,250).

Dedova I, Garrick T, Harper C. Human brain bank and donor programs for biomedical research into schizophrenia. Rebecca Cooper Medical Research Foundation, 2007 ($17,300).

Deng C. Antipsychotic drug-induced weight gain and expression of cholecystokinin receptors in the brainstem of rats. University of Wollongong Health & Behavioural Science Small Grant, 2007 ($12,500).

Karl T. Knockout mice for NPY and its various receptor subtypes – potential new animal models for mental illnesses. The Bill Ritchie Postdoctoral Research Fellowship, 2007-2010 ($300,000).

Loughland C. OU-2500 Hydraulic Chair. University of Newcastle, 2007 ($7,000).

Newell K. Cognitive behavioural changes induced by a double hit during brain development: Implications for schizophrenia. University of Wollongong Health and Behavioural Sciences Early Career Research Grant, 2007 ($2,285).

Newell K, Huang XF. Neuregulin 1 and ErbB4 mRNA and protein expression in schizophrenia. University Research Council Small Grants Scheme, 2007-2008 ($12,400).

Schall U (On behalf of: Brain Imaging Research Group at the PRC Brain & Mental Health). Upgrade of visual stimulus delivery facilities of new MRI scanner at John Hunter Hospital. University of Newcastle, 2007 ($79,000).

Schall U. Siemens diffusion tensor imaging acquisition software for Magnetom Avanto, University of Newcastle Faculty of Health Research Equipment, 2007 ($25,000).

Shannon Weickert C. Confocal microscope. Clive and Vera Ramaciotti Foundation Major Equipment Grant, 2007 ($30,000).

Solowij N, Yucel M, Lubman D, Ciarrochi J, Heaven P. Determining the cognitive sequelae of adolescent cannabis use: a longitudinal cohort study. NHMRC Project Grant, 2008-2010 ($252,125).

Tooney P, Cairns M. Investigation of genetic and epigentic mechanisms underlying dysregulation of RGS4 in schizophrenia. University of Newcastle Strategic Pilot Grant, 2007-2008 ($17,000).

Zavitsanou K. In vitro and in vivo imaging of cannabinoid-related targets. ANSTO Senior Research Fellowship, 2007-2009 ($450,000).

Research Degrees

Doctor of Philosophy

Dr Nathan Clunas, University of New South Wales

Dr Kelly Newell, University of Wollongong

Dr Penny Newson, University of Newcastle

Dr David Wheeler, University of Sydney

Masters / Clinical Doctorate

Louisa Gianacas, University of Newcastle

Honours

Erin Gardener, University of Newcastle

Amy Dawson, University of Wollongong

Summer Student Scholarships

Amy Dawson, University of Wollongong

Adam Carroll, University of Newcastle

Madeleine deVille, University of Newcastle

Scott McGreal, Macquarie University

Aditya Vyas, University of Sydney

2008

Publications Grants Research Degrees

Publications

Badcock JC, Chhabra S, Maybery M, Paulik G. Context binding and hallucination predisposition. Personality and Individual Differences 2008; 45: 822-827.

Beveridge N, Tooney P, Carroll A, Gardener E, Bowden N, Scott R, Tran N, Dedova I, Cairns M. miRNA expression in the temporal cortex in schizophrenia. Human Molecular Genetics 2008; 17:1156-1168.

Bowden N, Scott R, Tooney P. Altered expression in the superior temporal gyrus in schizophrenia. BMC Genomics 2008; 29:199-210.

Cairns, M. Small interfering RNAs and their therapeutic applications in mitigation of virus replication and pathological effects in the respiratory tract. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry2008; 7: 116-121.

Carr V, Lewin T, Sly K, Conrad A, Tirupati S, Cohen M, Ward P, Coombs T. Adverse incidents in acute psychiatric inpatient units: rates, correlates and pressures. Australian and New Zealand Journal of Psychiatry 2008; 42: 267-282.

Chetcuti A, Adams L, Mitchell P, Schofield P. Microarray gene expression profiling of mouse brain mRNA in a model of lithium chloride treatment. Psychiatric Genetics 2008; 18: 64-72.

Chong V, Beltaifa S, Thompson M, Law A, Webster M, Shannon Weickert C. Elevated Neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients. Schizophrenia Research 2008; 100: 270-280.

Chong V, Webster M, Shannon Weickert C. Specific developmental reductions in subventricular zone ErbB1 and ErbB4 mRNA in the human brain. International Journal of Developmental Neuroscience 2008; 26: 791-803.

Cohen M, Carr V, Solowij N. Cannabis, cannabinoids and schizophrenia: An integration of the evidence. Australian and New Zealand Journal of Psychiatry 2008; 42: 357-368.

Dean B, Karl T, Pavey G, Duffy L, Scarr E. Increased levels of seretonin 2A receptors and seretonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice. Schizophrenia Research 2008; 99: 341-349.

Doyle K, Karl T, Hort Y, Duffy L, Shine J, Herzog H. Y1 receptors are critical for the proliferation of adult mouse precursor cells in the olfactory neuroepithelium. Journal of Neurochemistry 2008; 105: 641-652.

du Bois T, Huang XF, Deng C. Perinatal administration of PCP alters adult behaviour in female Sprague-Dawley rats. Behavioural Brain Research2008; 188: 416-419.

du Bois T, Huang XF, Hsu CW, Li Y, Han M, Tan YY, Deng C. Altered dopamine receptor and transporter binding and tyrosine hydroxylase mRNA expression following perinatal NMDA receptor antagonism.Neurochemical Research 2008; 33: 1224-1231.

Duffy L, Cappas E, Scimone A, Schofield P, Karl T. Behavioural profile of a heterozygous mutant mouse model for EGF-like domain neuregulin 1.Behavioral Neuroscience 2008; 122: 748-759.

Duncan C, Chetcuti A, Schofield P. Gene expression co-regulated by treatment with clozapine, haloperidol or olanzapine in the mouse brain.Psychiatric Genetics 2008; 18: 226-239.

Green M, Waldron J, Simpson I, Coltheart M. Visual processing of social context during mental state perception in schizophrenia. Journal of Psychiatry and Neuroscience 2008; 33: 34-42.

Han M, Deng C, Burne T, Newell K, Huang XF. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology 2008; 33: 569-580.

Han M, Newell K, Zavitsanou K, Deng C, Huang XF. Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. Journal of Neuroscience Research 2008; 86: 457-464.

Henry J, Rendell P, Green M, McDonald S, O’Donnell M. Emotion regulation in schizophrenia: Affective, social and clinical correlates of suppression and reappraisal. Journal of Abnormal Psychology 2008; 117: 473-478.

Hinton T, Johnston G. The role of GABA-A receptors in schizophrenia.Cellscience Reviews 2008; 5: ISSN 1742-8130.

Karl T, Duffy L, Herzog H. Behavioural profile of a new mouse model for NPY deficiency. European Journal of Neuroscience 2008; 28: 173-180.

Kim WS, Shannon Weickert C, Garner B. Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. Journal of Neurochemistry 2008; 104: 1145-1166.

Michie PT, Budd B, Fulham WR, Hughes ME, Jamadar S, Johnston P, Karayanidis F, Matthews N, Rasser PE, Schall U, Thompson PM, Todd J , Ward PB, Yabe H. The potential for new understandings of normal and abnormal cognition by integration of neuroimaging and behavioral data: Not an exercise in bringing coals to Newcastle. Brain Imaging and Behavior 2008; 2: 318-326.

Paulik G, Badcock J, Maybery M. Dissociating the components of inhibitory control involved in predisposition to hallucinations. Cognitive Neuropsychiatry 2008; 13: 33-46.

Rossell S, Batty R. Elucidating semantic disorganisation from a word comprehension task: Do patients with schizophrenia and bipolar disorder show differential processing of nouns, verbs and adjectives?Schizophrenia Research 2008; 102: 63-68.

Russell T, Green M, Simpson I, Coltheart M. Remediation of facial emotion perception in schizophrenia: Concomitant changes in visual attention. Schizophrenia Research 2008; 103: 248-256.

Schall U. Dual constraints on synapse formation and regression in schizophrenia – More evidence required (Letter). Australian and New Zealand Journal of Psychiatry 2008; 42: 1069-1070.

Shannon Weickert C, Miranda-Angulo AL, Wong J, Perlman WR, Ward S, Radhakrishna V, Straub RE, Weinberger DR, Kleinman JE. Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Human Molecular Genetics 2008; 17: 2293-2309.

Shannon Weickert C, Rothmond D, Hyde T, Kleinman J, Straub R. Reduced dysbindin (DTNBP1) mRNA in hippocampus of patients with schizophrenia. Schizophrenia Research 2008; 98: 105-110.

Sheedy D, Garrick T, Dedova I, Hunt C, Miller R, Sundqvist N, Harper C. An Australian Brain Bank: a critical investment with a high return. Cell Tissue Banking 2008; 9: 205-216.

Skilbeck KJ, Hinton T, Johnston GAR. Sex-differences and stress: effects on regional high and low affinity [3H]GABA binding. Neurochemistry International 2008; 52: 1212-1219.

Skilbeck K, O’Reilly J, Johnston G, Hinton T. Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA-A receptor binding sites. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008; 32: 492-498.

Solowij N, Battisti R. The Chronic Effects of Cannabis on Memory in Humans: A Review. Current Drug Abuse Reviews 2008; 1: 81-98.

Spain D, Crilly J, Whyte I, Jenner L, Carr V, Baker A. Safety and effectiveness of high-dose midazolam for severe behavioural disturbance in an emergency department with suspected psychostimulant-affected patients. Emergency Medicine Australasia 2008; 20: 112-120.

Sundqvist N, Garrick T, Bishop I, Harper C. Reliability of post-mortem psychiatric diagnosis for neuroscience research. Australian and New Zealand Journal of Psychiatry 2008; 42: 221-227.

Todd J, Michie P, Schall U, Karayanidis F, Yabe H, Naatanen R. Deviant matters: duration, frequency and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia.Biological Psychiatry 2008; 63: 58-64.

Wang Q, Huang XF. Effects of chronic treatment of olanzapine and haloperidol on peptide YY binding densities in the rat brain. Experimental Neurology 2008; 209: 261-267.

Weston-Green KL, Huang XF, Han M, Deng C. The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: Implications for olanzapine-induced weight gain.International Journal of Neuropsychopharmocology 2008; 11: 827-835.

Yucel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C, Lubman D. Regional brain abnormalities associated with heavy long-term cannabis use. Archives of General Psychiatry 2008; 65: 694-701.

Zavitsanou K, Nguyen V, Newell K, Ballantyne P, Huang XF. Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: Implications for schizophrenia. Journal of Chemical Neuroanatomy 2008; 36:71-76.

Grants

Schizophrenia Research Institute Administered

Carr V, Schall U, Scott R, Jablensky A, Mowry B, Michie P, Catts S, Henskens F, Pantelis C, Loughland C, Tooney P. Revco Plus -86 Elite Upright Freezer. NHMRC Equipment Grant, 2008 ($3,224).

Duffy L, Draganic D, Carr V. The Australian Schizophrenia Research Bank: Freezer, State Trustees, 2008, ($9,000).

Karl T, Arnold J, McGregor I, Huang XF. Sensor rings (infrared beams) for open field apparatus (TruScan Coulbourn Instruments). NHMRC Equipment Grant, 2008 ($2,800).

Loughland CM. Visuo-cognition and emotion processing in schizophrenia. Schizophrenia International Research Society Conference Travel Grant, 2008 ($1,000).

Miller D, Karl T. Does genetic predisposition to schizophrenia alter the susceptibility to drugs of abuse in an animal model for this mental disorder? The Royal Australian and New Zealand College of Psychiatrists Young Investigator Grant, 2008 ($3,000).

Host Institution Administered

Cairns M, Tooney, P. A road map of schizophrenia associated gene and miRNA expression in the dorsolateral prefrontal cortex. Hunter Medical Research Institute Project Grant 2008 ($25,000).

Carr V, Schall U, Lewin T, Conrad A. A layered ten-year audit of clients presenting to a community-based service for young people at high risk of psychosis. Australian Rotary Health Research Fund Evaluation Grant, 2008 ($50,800).

Dedova I. Travel Grant to attend the ISBRA/RSA Joint 2008 Congress in Washington, D.C., USA. National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health (NIH), 2008 (A$2,800).

Du Bois TM. Perinatal NMDA receptor blockade alters D2, NMDA and M1/M4 receptors in later life: implications for pathological processes of schizophrenia. 1st Schizophrenia International Research Society Conference/Travel award, 2008 ($1,000).

Frank E. Evaluation of mGlu2/3 as a novel drug target in a genetic animal model for schizophrenia. University of Wollongong Research Committee Small Grant, 2008 ($13,407).

Green MJ. UNSW Vice-Chancellors Post-doctoral Fellowship, 2008-2010 ($215,705).

Green, MJ. Remediation of facial affect processing deficits in schizophrenia. Schizophrenia International Research Society Travel Award, 2008 ($1,000).

Harper C. Brain Tissue Resource Center for Alcohol Research. National Institutes of Health, National Institute On Alcohol Abuse And Alcoholism Grant, 2008-2012 ($2,495,279).

Huang XF. Dedicated radioactive laboratory equipment. NHMRC Equipment Grant, 2008 ($5,480).

Loo C, Mitchell P, Weickert T, Taylor J, Sachdev P. Machine for Transcranial Magnetic Stimulation (TMS). UNSW Major Research Equipment and Infrastructure Initiative, 2007 ($94,110).

Michie P, Budd B, Karayanidis F, Todd J, Smith, McKenzie, Hunter. Brain Electrical Source Analysis Software (BESA), NHMRC Equipment Grant, 2008 ($11,000).

Miller D, Karl T. Does genetic predisposition to schizophrenia (i.e. neuregulin 1 mutation) alter the susceptibility to drugs of abuse in an animal model for this mental disorder? NSW Institute for Psychiatry Fellowship 2008 ($63,350).

Newell K. An investigation of neuregulin 1 expression following perinatal NMDA hypofunction. UoW Faculty of Health and Behavioural Sciences Small Grant, 2008 ($5,000).

Newell, K. Are CB1 receptors more sensitive at adolescence than adulthood in Sprague-Dawley rats. UoW Faculty of Health and Behavioural Sciences Early Career Research Grant, 2008 ($3,000).

Shannon Weickert C. Enhancing neurogenesis in adult primate brain. UNSW Gold Star Award, 2008 ($40,000).

Tooney P, Cairns M, Scott R, Kelly B, Carr V. Neurobehavioural Genetics Network. NSW Health, 2008-2011 ($2,450,000).

Tooney, P, Michie, P, Schall, U, Scott, R, Stain, H, Atkinson. Brain science and young people’s mental health: a gene expression study in young people at ultra high risk of developing schizophrenia. Hunter Medical Research Institute Project Grant, 2008 ($25,000).

Weickert T, Weickert CS. Clinical trial of a selective estrogen receptor modulator in schizophrenia, UNSW Faculty Research Grant, 2008-2009 ($30,000).

Research Degrees

Doctor of Philosophy

Dr Retta Andresen, University of Wollongong

Masters / Clinical Doctorate

Gali Lawrence, University of Newcastle

Honours

Susan Gordon, University of Wollongong

Naomi Piyaratna, University of Wollongong

Sai Ruthirakumar, University of Wollongong

Danielle Santarelli, University of Newcastle

2009

Publications Grants Research Degrees

Publications

Bailey P, Henry J, Reed E. Schizophrenia and the display of embarrassment. Journal of Clinical and Experimental Neuropsychology2009; 31: 545-552.

Beveridge N, Tooney P, Carroll A, Tran N, Cairns M. Down-regulation of miR-17 family expression in response to retinoic acid induced neuronal differentiation. Cellular Signalling 2009; 21: 1837-1845.

Choi KH, Zepp ME, Wiggs B, Shannon Weickert C, Webster MJ. Expression profiles of schizophrenia susceptibility genes during human prefrontal cortical development. Journal of Psychiatry and Neuroscience2009; 34: 450-458.

Dalton VS, Wang HQ, Zavitsanou K. HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat. Neurochemical Research 2009; 34: 1343-1353.

Dedova I, Harding A, Sheedy D, Garrick T, Harper C. The Importance of Brain Banks for Molecular Neuropathological Research: The New South Wales Tissue Resource Centre Experience. International Journal of Molecular Sciences 2009; 10: 366-384.

Deng C, Kang K, Wang Q, Huang XF. Serotonin 2A receptor and its association with the pathology of schizophrenia (letter). Progress in Neuropsychopharmacology and Biological Psychiatry 2009; 33: 1585-1586.

du Bois T, Deng C, Han M, Newell KA, Huang XF. Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade. European Neuropsychopharmacology 2009; 19: 256-265.

du Bois T, Newel KA, Han M, Deng C, Huang XF. Perinatal PCP treatment alters the developmental expression of prefrontal and hippocampal muscarinic receptors. Progress in Neuropsychopharmacology & Biological Psychiatry 2009; 33: 37-40.

Duncan C, Schofield P, Weickert CS. Kv channel interacting protein 3 expression and regulation by haloperidol in midbrain dopaminergic neurons. Brain Research 2009; 1304: 1-13.

Frisoni G, Prestia A, Adorni A, Rasser P, Cotelli M, Soricelli A, Bonetti M, Geroldi C, Giannakopoulos P, Thompson P. In vivo neuropathology of cortical changes in elderly persons with schizophrenia. Biological Psychiatry 2009; 66: 578-585.

Garrick T, Sundqvist N, Dobbins T, Azizi L, Harper C. Factors that influence decisions by families to donate brain tissue for medical research. Cell and Tissue Banking 2009; 10: 309-315.

Glaw X, Garrick T, Terwee P, Patching J, Blake H, Harper C. Brain donation: who and why? Cell Tissue Banking 2009; 10: 241-246.

Green A, Garrick T, Sheedy D, Blake H, Shores A, Harper C. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary Australian normative data. Australian Journal of Psychology2008; 60: 72-79.

Green M. Physiological mechanisms of schizophrenia phenotypes: genes and receptors (pp. 298-299). In Abubaker, R. et al., Summary of the 1st Schizophrenia International Research Society Conference oral sessions, Venice, Italy, June 2125, 2008: The rapporteur reports. Schizophrenia Research 2008; 105: 289-383.

Han M, Huang XF, Deng C. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. International Journal of Neuropsychopharmacology 2009; 12: 941-952.

Han M, Huang XF, du Bois T, Deng C. The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain. Neuroscience 2009; 164: 1754-1763.

Hanlon MC, Karayanidis F, Schall U. Intact sensorimotor gating in adult attention deficit hyperactivity disorder. International Journal of Neuropsychopharmacology 2009; 12: 701-707.

Harris LW, Lockstone HE, Khaitovich P, Shannon Weickert C, Webster MJ, Bahn S. Gene expression in the prefrontal cortex during adolescence: implications for the onset of schizophrenia. BMC Medical Genomics 2009; 2: 28.

Huang XF, Chen JZ. Neuregulin 1, brain region specificity and PI3K/Akt in schizophrenia (Letter). European Archives of Psychiatry and Clinical Neuroscience 2009; 259: 307-308.

Kang K, Huang XF, Wang Q, Deng C. Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia – a postmortem study. Progress in Neuro-Psychopharmacology & Biological Psychiatry2009; 33: 867-871.

Kay-Lambkin F, Baker A, Lewin T, Carr V. Computer-based psychological treatment for comorbid depression and problematic alcohol and/or cannabis use: a randomized controlled trial of clinical efficacy. Addiction2009; 104: 378-388.

Kim S, Wong J, Shannon Weickert C, Garner B. Apolipoprotein-D expression is increased during development and maturation of the human prefrontal cortex. Journal of Neurochemistry 2009; 109: 1053-1066.

Lai A, Cairns M, Tran N, Zhang HP, Cullen L, Arndt G. RNA modulators of complex phenotypes in mammalian cells. PLoS ONE 2009; 4: e4758.

Langdon R, Jones SR, Connaughton E, Fernyhough C. The phenomenology of inner speech: Comparison of schizophrenia patients with auditory verbal hallucinations and healthy controls. Psychological Medicine 2009; 39: 655-663.

Langdon R, Ward P. Taking the perspective of the other contributes to awareness of illness in schizophrenia. Schizophrenia Bulletin 2009; 35: 1003-1011.

Law AJ, Pei Q, Walker M, Gordon-Andrews H, Shannon Weickert C, Feldon J, Pryce CR, Harrison PJ. Early parental deprivation in the marmoset monkey produces longterm changes in hippocampal expression of genes involved in synaptic plasticity and implicated in mood disorder. Neuropsychopharmacology 2009; 34: 1381-1394.

Loughland C, Lawrence G, Allen J, Hunter M, Lewin T, Oud N, Carr V. Aggression and trauma experiences among carer-relatives of people with psychosis. Social Psychiatry and Psychiatric Epidemiology 2009; 44: 1031-1040.

Morris R, Shannon-Weickert C, Loughland C. Emotional face processing in schizophrenia. Current Opinion in Psychiatry 2009; 22: 140-146.

Nesvaderani M, Matsumoto I, Sivagnanasundaram S. Anterior hippocampus in schizophrenia pathogenesis: molecular evidence from a proteome study. Australian and New Zealand Journal of Psychiatry 2009; 43: 310-322.

Paulik G, Badcock J, Maybery M. Intentional cognitive control impairments in schizophrenia: Generalized or specific? Journal of the International Neuropsychological Society 2009; 15: 982-989.

Pievani M, Rasser P, Galluzzi S, Benussi L, Ghidoni R, Sabattoli F, Bonetti M, Binetti G, Thompson P, Frisoni GB. Mapping the effect of APOE 4 on grey matter loss in Alzheimers disease in vivo. NeuroImage2009; 45: 1090-1098.

Richards AB, Morris RW, Ward S, Schimz S, Rothmond DA, Noble P, Woodward R, Winslow J, and Shannon Weickert, C. Gonadectony negatively impacts social behaviour in adolescent primates. Hormones & Behavior 2009; 56: 140-148.

Rubinov M, Knock S, Stam C, Michelaynnis S, Harris A, Williams L, Breakspear M. Small-world properties of nonlinear brain activity in schizophrenia. Human Brain Mapping 2009; 30: 403-416.

Schall U. Consciousness and hallucinations in schizophrenia: secondary aspects of generalized neuropil pathology? (Letter). Australian and New Zealand Journal of Psychiatry 2009; 43:393-394.

Shannon Weickert C, Elashoff M, Bahn S, Paabo S, Khaitchovitch P, Webster MJ. Transcriptome analysis of male-female differences in prefrontal cortical development (Letter). Molecular Psychiatry 2009; 14: 558-561.

Sly K, Lewin T, Carr V, Conrad A, Cohen M, Tirupati S, Ward P, Coombs T. Measuring observed mental state in acute psychiatric inpatients. Social Psychiatry and Psychiatric Epidemiology 2009; 44: 151-161.

Somel S, Franz H, Yan Z, Lorenc A, Guo S, Giger T, Kelso J, Nickel B, Dannemann M, Bahn S, Webster M, Shannon Weickert C, Lachmann M, Paabo S, Khaitovich P. Transcriptional neoteny in the human brain.Proceedings of the National Academy of Sciences 2009;106: 5743-5748.

Thienel R, Kellermann T, Schall U, Voss B, Reske M, Halfter S, Sheldrick AJ, Radenbach K, Habel U, Shah NJ, Kircher T. Muscarinic antagonist effects on executive control of attention. International Journal of Neuropsychopharmacology 2009; 12, 1307-1317.

Thienel R, Voss B, Kellermann T, Reske M, Halfter S, Sheldrick AJ, Radenbach K, Habel U, Schneider F, Shah NJ, Schall U, Kircher T. Nicotinic antagonist effects on functional attention networks. International Journal of Neuropsychopharmacology 2009; 12: 1295-1305.

Thompson M, Shannon Weickert C, Wyatt E, Webster MJ. Decreased glutamic acid decarboxylase 67 mRNA expression in multiple brain areas of patients with schizophrenia and other mental disorders. Journal of Psychiatric Research 2009; 43: 970-977.

van den Buuse, Wischhof L, Lee RX, Martin S, Karl T. Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. International Journal of Neuropsychopharmacology 2009; 12: 1383-1393.

Weickert T, Carr V, Weickert CS. Second generation antipsychotics reduce treatment discontinuation rates compared with haloperidol (Comment). Evidence Based Mental Health 2008; 11: 115.

Weidenhofer J, Scott R, Tooney P. Investigation of dysregulated cytomatrix active zone gene expression in the amygdala in schizophrenia: Effects of antipsychotic drugs. Journal of Psychiatric Research 2009 43: 282-290.

Wong J, Webster MJ, Cassano H, Shannon Weickert C. Changes in alternate brain-derived neurotrophic factor transcript expression in the developing human prefrontal cortex. European Journal of Neuroscience2009; 29: 1311-1322.

Wong J, Shannon Weickert C. Transcriptional interaction of an estrogen receptor splice variant and ErbB4 suggest convergence in gene susceptibility pathways in schizophrenia. Journal of Biological Chemistry2009; 284: 18824-18832.

Wye P, Bowman J, Wiggers J, Baker A, Knight J, Carr V, Terry M, Clancy R. Smoking restrictions and treatment for smoking: Policies and procedures in psychiatric inpatient units in Australia. Psychiatric Services2009; 60: 100-107.

Zhang X, Cairns M, Rose B, OBrien C, Shannon K, Clark K Gamble J, Tran N. Alterations in miRNA processing and expression in pleomorphic adenomas of the salivary gland. International Journal of Cancer 2009; 124: 2855-2863.

Grants

Schizophrenia Research Institute Administered

Arnold J, Karl T, McGregor I, Huang XF. Motion mensura moving tracking software for mouse behavioural testing. NHMRC Equipment Grant, 2009 ($2,000).

Carr V, Draganic D. The Australian Schizophrenia Research Bank. The Baxter Charitable Foundation and Merrett Foundation, 2009-2010 ($28,600).

Carr V, Michie P, Scott R, Schall U, Henskens F. Australian Schizophrenia Research Bank – Web Interface and Tools (ASRB). Intersect, 2009 (in kind support for IT developers to the value of $600,000).

Catts S, Carr V, Loughland C, Draganic D. Australian Schizophrenia Research Bank- Queensland. Sylvia and Charles Viertel Foundation General Program Grant, 2009-2011 ($210,000).

Dalton V. Adolescent rats show a reduced neurochemical reaction compared to adults in response to cannabinoid administration. Ian Potter Foundation Travel Grant, 2009 ($1,929).

Draganic D, Carr V. Schizophrenia Research Institute and ANSTO Postdoctoral Fellowship in Schizophrenia Research. ANSTO, 2009-2012 ($134,363).

Duffy L, Draganic D, Carr V. The Australian Schizophrenia Research Bank. Trust Company 2009 Grant, 2009-2010 ($30,000).

Karl T. International Congress on Schizophrenia Research, San Diego 2009, CASS Foundation Travel Grant 2008 ($3,094).

Karl T. International Congress on Schizophrenia Research, San Diego 2009. Ian Potter Foundation Travel Award, 2009 ($2,500).

Host Institution Administered

Arnold J. Role of ABC transporter in resistance to antipsychotic therapy and cannabinoid-antipsychotic drug interactions. NARSAD Young Investigator Award, 2009-2010 ($79,239).

Cairns M. Neurodevelopmental model of schizophrenia-associated changes in gene silencing. NARSAD Young Investigator Award, 2009-2010 ($83,489).

Cairns M, Wu J, Tooney P, Scott R. Analysis of schizophrenia-associated gene and microRNA signatures in purified CD4 and CD8 positive T cells. HMRI Youth Research Project Grant, 2009-2010 ($25,000).

Carr V, Michie P, Karayanidis F and Holbrook A. Longitudinal Child Health Study: Stage 1 Pilot Study. University of Newcastle Data Linkage Credits, 2009 ($11,700).

Catts V. FAS-cinating changes in a death receptor pathway in schizophrenia. Stanley Medical Research Institute Neuropathology Research Grant, 2009-2010 ($190,823).

Frank E. Schizophrenia perturbs inflammation challenging an animal model for schizophrenia. University of Wollongong URC Small Grant, 2009 ($15,500).

Frank E, Huang XF, Newell K, Deng C, Han M. Monitoring drug-induced changes of neurotransmission in vivo: A microdialysis approach in an animal model of schizophrenia. Clive and Vera Ramaciotti Foundation Establishment Grant, 2009 ($30,000).

Fung S. International Brain Research Organization International Travel Grant, 2009 ($2,180).

Halliday G, Double K, Shannon Weickert C. Effect of Parkinson’s disease and L-dopa therapy on neurogenesis. Parkinsons NSW Unity Walk Research Grant, 2009 ($50,000).

Hodgson DM, Nakamura T, Michie PT, Todd J, Hunter M. Mismatch negativity (MMN) in a rodent model of schizophrenia. Centre for Brain and Mental Health Research, University of Newcastle, Summer Scholarship Program Research Projects, 2009-2010 ($1,000).

Hodgson DM, Nakamura T, Michie PT, Hunter M. Development of an animal model of schizophrenia-like endophenotype induced by early-life infection. Centre for Brain and Mental Health Research, University of Newcastle 2009 Publication Performance Grant, 2009 ($3,500).

Huang XF, Deng C. The role of histamine, NYP and melanocortin systems in the development and prevention of olanzapine-induced obesity. University Research Council Near Miss Grant, University of Wollongong, 2009 ($15,000).

Huang XF, Deng C, Newell K, Fernandez F. Molecular Pathology Infrastructure, Research Infrastructure Block Grant, 2009-2010, ($72,000).

Huang XF, Newell K. NMDA receptor/neuregulin1 signalling in response to phencyclidine administration. NHMRC Project Grant, 2009-2011, ($417,750).

Karl T. How genetic and environmental risk factors interactively impact on animal models for schizophrenia. NHMRC Career Development Award, 2009-2012 ($370,000).

Karl T. The role of cannabis in animals genetically predisposed to schizophrenia. NARSAD Young Investigator Award, 2009-2010 ($83,484).

McCabe K. Faculty of Health Grant-in-Aid, University of Newcastle, 2009 ($5,000).

Schall U, Michie P, Stain H, Ward P, Langdon R, Todd J, Rasser P, Carr V, Weickert T. Understanding emerging severe mental illness in young people. NHMRC Project Grant, 2009-2013 ($1,505,750).

Shannon Weickert C. Abnormalities of the human glucocorticoid receptor in schizophrenia and bipolar disorder. Stanley Medical Research Institute Neuropathology Research Grant, 2009-2010 ($156,760).

Solowij N. Do genetic polymorphisms underlie the propensity for cannabis to cause cognitive deficits, psychiatric symptoms and structural brain changes? University of Wollongong URC Small Grant, 2009 ($14,460).

Walker R, Dayas C, Spratt N, Tooney P. An XYZ motorised microscope stage for use in a setup to perform advanced neuron reconstruction, 3D mapping of neuronal structures and morphometry analysis. Hunter Medical Research Institute PRC CBMHR Infrastructure funding, 2009 ($10,000).

Weickert T, Weickert CS, Schofield P, Kulkarni J, Carr V. Cognitive enhancement in schizophrenia via selective oestrogen receptor modulator. NHMRC Project Grant, 2009-2011, ($381,150).

Wong J. Molecular Mechanisms Leading to Schizophrenia- The Role of Estrogen and Estrogen Receptor Alpha. NHMRC Training Fellowship, 2009-2012, ($285,000).

Wong J. Postdoctoral Trainee Travel Award, Society for Neuroscience, 2009 ($2,600).

Research Degrees

Doctor of Philosophy

Dr Carlotta Duncan, University of New South Wales

Dr Natasha Matthews, University of Newcastle

Dr Georgina Paulik, University of Western Australia

Dr Kelly Skilbeck, University of Sydney

Doctorate of Clinical Psychology

Ms Alison Beck, University of Newcastle

Honours

Ms Kristen Vallender , University of Newcastle

Ms Dominique Rich, University of Newcastle

Mr Rajesh Pathy , University of Wollongong

Mr Cameron Warren , University of Wollongong